var title_f22_53_23376="Gram stain sputum 8";
var content_f22_53_23376=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F57623&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F57623&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gram stain sputum 8",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 233px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_53_23376=[""].join("\n");
var outline_f22_53_23376=null;
var title_f22_53_23377="Allergic conjunctivitis";
var content_f22_53_23377=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F79978&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F79978&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Allergic conjunctivitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 239px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Allergic conjunctivitis typically presents as bilateral redness, watery discharge, and itching.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Trobe, JD. The Eyes Have It: An interactive teaching and assessment program on vision care. WK Kellog Eye Center, University of Michigan. Copyright &copy; Jonathan D Trobe, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_53_23377=[""].join("\n");
var outline_f22_53_23377=null;
var title_f22_53_23378="Zygomaticomaxillary complex fractures";
var content_f22_53_23378=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F55561&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F55561&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Zygomaticomaxillary complex fractures",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 418px; height: 322px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Zygomaticomaxillary complex (ZMC, tripod, or malar) fractures are sustained with direct blunt trauma to the zygomatic buttress of the face. The zygoma has four major stability points, with connections as follows: (a) the frontal bone at the frontozygomatic suture; (b) the maxilla at the medial inferior orbital rim; (c) at the zygomaticomaxillary buttress; and (d) the temporal bone at the zygomatic arch. A complete fracture of the complex usually involves all four of these points. Anteriorly, the fracture usually occurs through the infraorbital foramen because of the bone's relative weakness. Physical findings associated with ZMC fractures are numbness or paresthesias (CN V), depression of the zygomatic eminence, ocular dystopia (uneven pupillary levels), lateral canthal ptosis, enophthalmos, and palpable fractures at the inferior and lateral orbital rims.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Ochs MW. Bony Oral-Maxillofacial Injuries. In: The Trauma Manual: Trauma and Acute Care Surgery, 3rd edition, Peitzman AB, Rhodes M, Schwab CW, et al. (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_53_23378=[""].join("\n");
var outline_f22_53_23378=null;
var title_f22_53_23379="Tumor bleeding 15b";
var content_f22_53_23379=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F69719&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F69719&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 521px\">",
"   <div class=\"ttl\">",
"    Selective right internal pudendal angiogram",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 501px; height: 606px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Selective right internal pudendal angiogram shows a prominent right cervicovaginal artery supplying a hypervascular metastatic renal cell carcinoma of the vagina (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_53_23379=[""].join("\n");
var outline_f22_53_23379=null;
var title_f22_53_23380="Cerebral paragonimiasis";
var content_f22_53_23380=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F73979&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F73979&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 604px\">",
"   <div class=\"ttl\">",
"    Cerebral paragonimiasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 584px; height: 201px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    24-year-old woman who has had a positive ELISA reaction for",
"    <em>",
"     Paragonimus",
"    </em>",
"    -specific antibody in CSF since her first MR examination.",
"    <br>",
"     (A) T1-weighted (500/30) axial image from initial MR study shows subacute hemorrhages of high signal intensity (arrows) in occipital lobes bilaterally, presumably due to vascular involvement of",
"     <em>",
"      Paragonimus",
"     </em>",
"     . No other abnormality was seen on initial study.",
"     <br>",
"      (B, C) Follow-up MR images obtained two months later, after no specific treatment. Contrast-enhanced T1-weighted image (B) shows multiple, conglomerated, ring-enhancing lesions with surrounding edema in right frontal lobe. On unenhanced T2-weighted (3000/80) image (C), walls of rings appear either isointense (arrow) or hypointense (arrowhead) relative to lesions. Hemorrhages in occipital lobes were markedly absorbed (not shown).",
"      <em>",
"       Paragonimus",
"      </em>",
"      eggs were found in a lesion of the right frontal lobe during surgery.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"       Reprinted with permission from: the American Journal of Roentgenology. Cha SH, Chang KH, Cho SY, et al. Cerebral paragonimiasis in early active stage: CT and MR features. AJR Am J Roentgenol 1994; 162:141. Copyright &copy; 1994 American Roentgen Ray Society.",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_53_23380=[""].join("\n");
var outline_f22_53_23380=null;
var title_f22_53_23381="Hydrocodone and acetaminophen: Patient drug information";
var content_f22_53_23381=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Hydrocodone and acetaminophen: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/51/43832?source=see_link\">",
"     see \"Hydrocodone and acetaminophen: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/34/22055?source=see_link\">",
"     see \"Hydrocodone and acetaminophen: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F179839\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      hycet&reg;;",
"     </li>",
"     <li>",
"      Lorcet&reg; 10/650;",
"     </li>",
"     <li>",
"      Lorcet&reg; Plus;",
"     </li>",
"     <li>",
"      Lortab&reg;;",
"     </li>",
"     <li>",
"      Margesic&reg; H;",
"     </li>",
"     <li>",
"      Maxidone&reg;;",
"     </li>",
"     <li>",
"      Norco&reg;;",
"     </li>",
"     <li>",
"      Stagesic&trade;;",
"     </li>",
"     <li>",
"      Vicodin ES&reg;;",
"     </li>",
"     <li>",
"      Vicodin HP&reg;;",
"     </li>",
"     <li>",
"      Vicodin&reg;;",
"     </li>",
"     <li>",
"      Xodol&reg; 10/300;",
"     </li>",
"     <li>",
"      Xodol&reg; 5/300;",
"     </li>",
"     <li>",
"      Xodol&reg; 7.5/300;",
"     </li>",
"     <li>",
"      Zamicet&trade;;",
"     </li>",
"     <li>",
"      Zolvit&reg;;",
"     </li>",
"     <li>",
"      Zydone&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F13153914\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3491790",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Acetaminophen may cause very bad liver problems. Your risk is higher if you take more than 4 grams of acetaminophen a day, drink beer, wine, or mixed drinks, or have liver disease. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700435",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You will be watched closely to make sure you do not misuse, abuse, or become addicted to this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10027585\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease pain.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10027584\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702253",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to hydrocodone, acetaminophen, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10027589\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be habit-forming with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696680",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid other sources of acetaminophen. An overdose may cause problems.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697135",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a history of a drug or drinking problem, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697302",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor. You may be more sensitive to this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before you use other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696699",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful if you have G6PD deficiency. Anemia may happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10027590\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698201",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the liver may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10027592\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699000",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Poor pain control.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699014",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10027587\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3927405",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug with other strong pain drugs or if you are using a pain patch without talking to your doctor first.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694263",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (elixir, solution) if you cannot swallow pills.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694768",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take more than what your doctor told you to take. Liver problems may happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698543",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a pain diary.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10027588\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10027593\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10027594\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12537 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-221.179.173.170-7B5B02C4AA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_53_23381=[""].join("\n");
var outline_f22_53_23381=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179839\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13153914\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027585\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027584\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027589\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027590\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027592\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027587\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027588\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027593\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027594\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?42/51/43832?source=related_link\">",
"      Hydrocodone and acetaminophen: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/34/22055?source=related_link\">",
"      Hydrocodone and acetaminophen: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_53_23382="Lisdexamfetamine: Drug information";
var content_f22_53_23382=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Lisdexamfetamine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?30/44/31429?source=see_link\">",
"    see \"Lisdexamfetamine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/14/37094?source=see_link\">",
"    see \"Lisdexamfetamine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709015\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F4425746\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Vyvanse&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F10170113\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Vyvanse&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F4425750\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Central Nervous System Stimulant",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F6126904\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      ADHD:",
"     </b>",
"     Oral: Initial: 30 mg once daily in the morning; may increase in increments of 10 mg or 20 mg/day at weekly intervals until optimal response is obtained; maximum: 70 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Individualize dosage based on patient need and response to therapy. Administer at the lowest effective dose.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F4425789\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/14/37094?source=see_link\">",
"      see \"Lisdexamfetamine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      ADHD:",
"     </b>",
"     Oral: Children &ge;6 years and Adolescents: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F4425793\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral, as dimesylate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vyvanse&reg;: 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F4425748\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F4425744\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-II",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874689\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089823.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089823.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F4425790\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer in the morning without regard to meals; swallow capsule whole, do not chew; capsule may be opened and the entire contents dissolved in glass of water; stir until dispersed completely and consume the resulting solution immediately; do not store solution.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F4425751\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of attention-deficit/hyperactivity disorder (ADHD)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F4425741\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Vyvanse&reg; may be confused with Visanne&reg;, ViVAXIM&reg;, Vytorin&reg;, Glucovance&reg;, Vivactil&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F4425762\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Insomnia (13% to 27%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Appetite decreased (children and adolescents 34% to 39%; adults 27%), xerostomia (adults 26%; children and adolescents 4% to 5%), abdominal pain (children 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Blood pressure increased (adults 3%), heart rate increased (adults 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Irritability (children 10%), anxiety (adults 6%), dizziness (children 5%), jitteriness (adults 4%), affect lability (children 3%), agitation (adults 3%), restlessness (adults 3%), fever (children 2%), somnolence (children 2%), tic (children 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Hyperhidrosis (adults 3%), rash (children 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Vomiting (children 9%), weight loss (children and adolescents 9%; adults 3%), diarrhea (adults 7%), nausea (6% to 7%), anorexia (adults 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Genitourinary: Erectile dysfunction (adults 3%), libido decreased (adults &lt;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Tremor (adults 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Dyspnea (adults 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Postmarketing and/or case reports (Limited to important or life-threatening): Accommodation abnormal, aggression, anaphylactic reaction, angioedema, cardiomyopathy, depression, dermatillomania, diplopia, eosinophilic hepatitis, hallucination, hypersensitivity, logorrhea, mania, mydriasis, psychotic episodes, seizure, Stevens-Johnson syndrome",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Additional adverse reaction associated with amphetamines; frequency not defined:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Cardiovascular: Hypertension, MI, sudden death, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Central nervous system: Exacerbation of motor and phonic tics, overstimulation, stroke, Tourette's syndrome",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Dermatologic: Toxic epidermal necrolysis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Gastrointestinal: Abnormal taste, constipation",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F4425757\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to amphetamine products or any component of the formulation; use during or within 14 days following MAO inhibitor therapy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F4425758\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular events: Sudden death, stroke, and myocardial infarction have been reported in adults receiving the recommended doses of CNS stimulants. In children and adolescents with pre-existing structural cardiac abnormalities or other serious heart problems, sudden death has been reported while receiving the recommended doses of CNS stimulants for ADHD. These products should be avoided in the patients with known serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease (adults), or other serious cardiac problems that could increase the risk of sudden death that these conditions alone carry. Patients should be carefully evaluated for these cardiac disorders prior to initiation of therapy. Patients who develop symptoms of cardiac disease (eg, chest pain, syncope) should be evaluated promptly. CNS stimulants may increase heart rate (~ mean increase: 3-6 bpm); monitor for adverse events related to tachycardia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS effects: Amphetamines may impair the ability to engage in potentially hazardous activities.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Visual disturbance: Difficulty in accommodation and blurred vision has been reported with the use of stimulants.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Abuse/misuse/diversion:",
"     <b>",
"      [U.S. Boxed Warning]: CNS stimulants (including lisdexamfetamine) have a high potential for abuse and dependence; assess for abuse potential prior to use and monitor for signs of abuse and dependence during therapy.",
"     </b>",
"     Use with caution in patients with history of ethanol or drug abuse. Prescriptions should be written for the smallest quantity consistent with good patient care to minimize possibility of overdose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; ADHD treatment: Appropriate use: Recommended to be used as part of a comprehensive treatment program for attention deficit disorders. When used for extended periods, therapy should be periodically re-evaluated to determine if continued treatment is necessary; if possible, interrupt therapy to assess if behavioral symptoms recur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypertension: CNS stimulants may increase blood pressure (~ mean increase: 2-4 mm Hg); monitor for adverse events related to hypertension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Psychiatric disorders: Use with caution in patients with pre-existing psychosis, bipolar disorder (may induce mixed/manic episode), aggressive behavior, or hostility. May exacerbate symptoms of behavior and thought disorder in psychotic patients; new onset psychosis or mania may occur with stimulant use; observe for symptoms of aggression and/or hostility.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorder: Use with caution in patients with a history of seizure disorder; may lower seizure threshold leading to new onset or breakthrough seizure activity. Discontinue if seizures occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tourette's syndrome/tics: Use with caution in patients with Tourette's syndrome; stimulants may exacerbate tics (motor and phonic) and Tourette&rsquo;s syndrome. Evaluate for tics and Tourette&rsquo;s syndrome prior to therapy initiation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use caution in this age group due to CNS stimulant adverse effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Appetite suppression may occur; monitor weight during therapy, particularly in children. Use of stimulants has been associated with slowing of growth rate; monitor growth rate during treatment. Treatment interruption may be necessary in patients who are not growing or gaining weight as expected. Safety and efficacy of long-term use in children have not yet been established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Discontinuation of therapy: Abrupt discontinuation following high doses or for prolonged periods may result in symptoms for withdrawal.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299610\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F4425767\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alkalinizing Agents: May decrease the excretion of Amphetamines.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ammonium Chloride: May decrease the serum concentration of Amphetamines. This effect is likely due to an enhanced excretion of amphetamines in the urine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Analgesics (Opioid): Amphetamines may enhance the analgesic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the excretion of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihistamines: Amphetamines may diminish the sedative effect of Antihistamines.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May diminish the stimulatory effect of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May decrease the excretion of Amphetamines.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ethosuximide: Amphetamines may diminish the therapeutic effect of Ethosuximide. Amphetamines may decrease the serum concentration of Ethosuximide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestinal Acidifying Agents: May decrease the serum concentration of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ioflupane I 123: Amphetamines may diminish the diagnostic effect of Ioflupane I 123.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: May diminish the stimulatory effect of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypertensive effect of Amphetamines.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methenamine: May decrease the serum concentration of Amphetamines. This effect is likely due to an enhanced excretion of amphetamines in the urine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PHENobarbital: Amphetamines may decrease the serum concentration of PHENobarbital.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Amphetamines may decrease the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proton Pump Inhibitors: May increase the serum concentration of Amphetamines. Specifically, data indicate that Proton Pump Inhibitors may increase the rate at which Amphetamines are absorbed.  Total exposure to Amphetamines is not significantly changed.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: May enhance the stimulatory effect of Amphetamines. Tricyclic Antidepressants may also potentiate the cardiovascular effects of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F4425771\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Ethanol may increase CNS depression. Caffeine use may worsen problems with sleeping, headache, irritability, dizziness, nausea, vomiting, abdominal pain, and decreased appetite. Management: Avoid ethanol and caffeine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: High-fat meal prolongs T",
"     <sub>",
"      max",
"     </sub>",
"     by ~1 hour.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F4425752\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F4425753\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse effects have not been observed in animal reproduction studies. Lisdexamfetamine is converted to dextroamphetamine. The majority of human data is based on illicit amphetamine/methamphetamine exposure and not from therapeutic maternal use (Golub, 2005). Use of amphetamines during pregnancy may lead to an increased risk of premature birth and low birth weight; newborns may experience symptoms of withdrawal. Behavioral problems may also occur later in childhood (LaGasse, 2012).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F4425755\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F4425756\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The majority of human data is based on illicit amphetamine/methamphetamine exposure and not from therapeutic maternal use (Golub, 2005). Amphetamines are excreted into breast milk and use may decrease milk production. Increased irritability, agitation, and crying have been reported in nursing infants (ACOG, 2011). According to the manufacturer, the decision to continue or discontinue breast-feeding during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F5989464\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Vyvanse Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (100): $682.57",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg (100): $682.57",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg (100): $682.57",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (100): $682.57",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     60 mg (100): $682.57",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     70 mg (100): $682.57",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F4425792\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cardiac evaluation should be completed on any patient who develops chest pain, unexplained syncope, and any symptom of cardiac disease during treatment with stimulants; growth (height and weight) in children; CNS activity in all patients; signs of misuse, abuse, or addiction",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     When used for the treatment of ADHD, thoroughly evaluate for cardiovascular risk. Monitor heart rate, blood pressure, and consider obtaining ECG prior to initiation (Vetter, 2008).",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F4425785\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Lisdexamfetamine dimesylate is a prodrug that is converted to the active component dextroamphetamine (a noncatecholamine, sympathomimetic amine). Amphetamines are noncatecholamine, sympathomimetic amines that cause release of catecholamines (primarily dopamine and norepinephrine) from their storage sites in the presynaptic nerve terminals.  A less significant mechanism may include their ability to block the reuptake of catecholamines by competitive inhibition.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F4425774\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Dextroamphetamine: V",
"     <sub>",
"      d",
"     </sub>",
"     : Adults: 3.5-4.6 L/kg; distributes into CNS; mean CSF concentrations are 80% of plasma",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Metabolized in the blood by hydrolytic activity of red blood cells to dextroamphetamine and l-lysine; does not undergo CYP mediated metabolism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Lisdexamfetamine: &lt;1 hour; Dextroamphetamine: 10-13 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: T",
"     <sub>",
"      max",
"     </sub>",
"     : Lisdexamfetamine: ~1 hour; Dextroamphetamine: ~3.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (96%, 42% as amphetamine-related compounds, 2% as lisdexamfetamine, 25% hippuric acid); feces (minimal)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American College of Obstetricians and Gynecologists (ACOG) Committee Opinion: No. 479, &ldquo;Methamphetamine Abuse in Women of Reproductive Age,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2011, 117(3):751-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/53/23382/abstract-text/21343793/pubmed\" id=\"21343793\" target=\"_blank\">",
"        21343793",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chiang WK, &ldquo;Amphetamines,&rdquo;",
"      <i>",
"       Goldfrank's Toxicologic Emergencies",
"      </i>",
"      , 8th edition, Flomenbaum NE, Goldfrank LR, Hoffman RS, et al, eds, New York: The McGraw-Hill Companies, Inc, 2006, 1119.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cooper WO, Habel LA, Sox CM, et al, &ldquo;ADHD Drugs and Serious Cardiovascular Events in Children and Young Adults,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2011, 365(20):1896-904.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/53/23382/abstract-text/22043968/pubmed\" id=\"22043968\" target=\"_blank\">",
"        22043968",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Golub M, Costa L, Crofton K, et al, \"NTP-CERHR Expert Panel Report on the Reproductive and Developmental Toxicity of Amphetamine and Methamphetamine,\"",
"      <i>",
"       Birth Defects Res B Dev Reprod Toxicol",
"      </i>",
"      , 2005, 74(6):471-584.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/53/23382/abstract-text/16167346/pubmed\" id=\"16167346\" target=\"_blank\">",
"        16167346",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Habel LA, Cooper WO, Sox CM, et al, &ldquo;ADHD Medications and Risk of Serious Cardiovascular Events in Young and Middle-Aged Adults,&rdquo; 2011,",
"      <i>",
"       JAMA",
"      </i>",
"      , 306(24):2673-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/53/23382/abstract-text/22161946/pubmed\" id=\"22161946\" target=\"_blank\">",
"        22161946",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      LaGasse LL, Derauf C, Smith LM, et al, \"Prenatal Methamphetamine Exposure and Childhood Behavior Problems at 3 and 5 Years of Age,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2012, 129(4):681-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/53/23382/abstract-text/22430455/pubmed\" id=\"22430455\" target=\"_blank\">",
"        22430455",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Health and Clinical Excellence (NICE), National Collaborating Centre for Mental Health , &ldquo;Attention Deficit Hyperactivity Disorder, The NICE Guideline on Diagnosis and Management of ADHD in Children, Young People and Adults,&rdquo; National Clinical Practice Guideline Number 72, 2008:1-664. Available at  www.nice.org.uk/cg072",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nissen SE, &ldquo;ADHD and Cardiovascular Risk,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2006, 354:1445-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/53/23382/abstract-text/16549404/pubmed\" id=\"16549404\" target=\"_blank\">",
"        16549404",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pliszka S and AACAP Work Group on Quality Issues, &ldquo;Practice Parameter for the Assessment and Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder,&rdquo;",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 2007, 46(7):894-921.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/53/23382/abstract-text/17581453/pubmed\" id=\"17581453\" target=\"_blank\">",
"        17581453",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vetter VL, Elia J, Erickson CH, et al,  &ldquo;Cardiovascular Monitoring of Children and Adolescents With Heart Disease Receiving Stimulant Drugs. A Scientific Statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2008, 117:2407-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/53/23382/abstract-text/18427125/pubmed\" id=\"18427125\" target=\"_blank\">",
"        18427125",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Westfall TC, Westfall DP, &ldquo;Adrenergic Agonists and Antagonists,&rdquo;",
"      <i>",
"       Goodman and Gilman's The Pharmacological Basis of Therapeutics",
"      </i>",
"      , 11th ed, Brunton LL, ed, New York, NY: McGraw-Hill, 2006, 257-8.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10143 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-210.101.131.232-B327878308-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_53_23382=[""].join("\n");
var outline_f22_53_23382=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709015\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4425746\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10170113\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4425750\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6126904\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4425789\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4425793\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4425748\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4425744\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874689\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4425790\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4425751\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4425741\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4425762\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4425757\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4425758\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299610\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4425767\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4425771\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4425752\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4425753\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4425755\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4425756\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5989464\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4425792\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4425785\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4425774\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10143\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10143|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?30/44/31429?source=related_link\">",
"      Lisdexamfetamine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/14/37094?source=related_link\">",
"      Lisdexamfetamine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_53_23383="Treatment of secondary (AA) amyloidosis";
var content_f22_53_23383=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of secondary (AA) amyloidosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/53/23383/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/53/23383/contributors\">",
"     Peter D Gorevic, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/53/23383/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/53/23383/contributors\">",
"     Peter H Schur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/53/23383/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/53/23383/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/53/23383/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Secondary (AA) amyloidosis is a disorder characterized by the extracellular tissue deposition of fibrils composed of fragments of serum amyloid A protein (SAA), an acute phase reactant. AA amyloidosis can complicate a number of chronic inflammatory conditions, including rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), and ankylosing spondylitis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/53/23383/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30086?source=see_link\">",
"     \"Pathogenesis of secondary (AA) amyloidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;If untreated, AA amyloidosis is a serious disease with a significant mortality due to end-stage renal disease, infection, heart failure, bowel perforation, or gastrointestinal bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?22/53/23383/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Patients with persistently high circulating levels of SAA are at particular risk to develop these complications of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?22/53/23383/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. A progressive improvement in survival rates has been reported among patients with AA amyloidosis, likely reflecting, in part, improved treatment strategies for associated inflammatory disorders, as well as earlier detection [",
"    <a class=\"abstract\" href=\"UTD.htm?22/53/23383/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a review of 374 cases of AA amyloidosis, for example, mean survival from diagnosis was 133 months, with older age, reduced serum albumin concentration, end-stage renal failure at baseline, and the degree by which the SAA concentration was elevated during follow-up being of poorer prognostic significance [",
"    <a class=\"abstract\" href=\"UTD.htm?22/53/23383/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Importance of control of the underlying disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Successful treatment of the underlying inflammatory process (as with surgical resection of the focus of infection or tumor), such as cytotoxic agents",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    biological agents in rheumatoid arthritis or antibiotics with chronic infection, can lead to stabilization of or improvement in renal function, to reduction in protein excretion, and to partial resolution of amyloid deposits (as assessed in some studies by scintigraphy with radiolabeled SAP) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/53/23383/abstract/6-12\">",
"     6-12",
"    </a>",
"    ]. This was illustrated in a report of 80 patients with AA amyloid, mostly due to juvenile idiopathic arthritis or to rheumatoid arthritis, who were prospectively followed for a median of four years; in this series, the systemic amyloid load was assessed by yearly SAP scintigraphy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/53/23383/abstract/13\">",
"     13",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Forty-two patients had median serum SAA concentration within the reference range (&lt;10",
"      <span class=\"nowrap\">",
"       mg/L);",
"      </span>",
"      amyloid deposits regressed in 25 and stabilized in 14. Among patients with renal disease at baseline, proteinuria typically fell, while the serum creatinine concentration was either stable or improved. Two patients who required dialysis remained on dialysis.",
"     </li>",
"     <li>",
"      The outcomes were variable in the other patients. However, among those in whom the serum SAA was persistently above 50",
"      <span class=\"nowrap\">",
"       mg/L,",
"      </span>",
"      the amyloid load usually increased, and organ function deteriorated. In one patient who underwent renal transplantation, proteinuria and renal amyloid deposits recurred within 36 months.",
"     </li>",
"     <li>",
"      There was a variable relation between changes in amyloid load and changes in organ function. In some patients, for example, renal function was stable despite a reduction in amyloid load, while others had improved renal function despite a stable amyloid load.",
"     </li>",
"     <li>",
"      The estimated 10-year survival was much higher in the patients with median serum SAA below 10",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"      (90 versus 40 percent in those with higher median values), with 60 percent regression as assessed by I-123-labeled SAP scintigraphy, if this level was maintained [",
"      <a class=\"abstract\" href=\"UTD.htm?22/53/23383/abstract/3,13\">",
"       3,13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar findings have been noted in other uncontrolled series [",
"    <a class=\"abstract\" href=\"UTD.htm?22/53/23383/abstract/6,7,10-12,14-16\">",
"     6,7,10-12,14-16",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a 10- to 20-year follow-up of 16 adults given alkylating agents because of AA amyloid due to rheumatic disease (rheumatoid arthritis, ankylosing spondylitis, or juvenile chronic polyarthritis), treated patients had substantial preservation of renal function compared with 48 untreated controls [",
"      <a class=\"abstract\" href=\"UTD.htm?22/53/23383/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In three patients with Crohn&rsquo;s disease who underwent kidney transplantation because of renal amyloidosis, immunosuppressive therapy led to remission of the inflammatory bowel disease [",
"      <a class=\"abstract\" href=\"UTD.htm?22/53/23383/abstract/7\">",
"       7",
"      </a>",
"      ]. Serial SAP scintigraphy demonstrated regression of amyloid deposits in two patients and stabilization of amyloid in the third.",
"     </li>",
"     <li>",
"      In four patients with systemic AA amyloidosis complicating Castleman&rsquo;s disease (angiofollicular lymph node hyperplasia), resection of the tumors may have led to clinical regression of the amyloid, which was also corroborated by SAP scintigraphy [",
"      <a class=\"abstract\" href=\"UTD.htm?22/53/23383/abstract/9,17\">",
"       9,17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     TREATMENT OF AA AMYLOIDOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As illustrated by the preceding observations, the preferred therapy of AA amyloid is control of the underlying inflammatory disease. As examples,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    has become accepted therapy for secondary amyloidosis, particularly in familial Mediterranean fever, and anti-proinflammatory cytokines (IL-1&beta;, TNF-&alpha;, IL-6) have been shown to have efficacy in some cases of AA amyloidosis due to rheumatic disorders and to hereditary autoinflammatory disease. Agents under development interfere with fibril formation. The efficacy of dialysis and renal transplantation in those patients who progress to end-stage renal disease is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/29/13784?source=see_link\">",
"     \"Renal amyloidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Colchicine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     Colchicine",
"    </a>",
"    has become accepted prophylactic therapy to prevent secondary amyloidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/53/23383/abstract/18\">",
"     18",
"    </a>",
"    ]. In familial Mediterranean fever (FMF), for example, colchicine (in a dose of 0.6 to 1.2",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    markedly reduced the frequency of attacks of abdominal pain, diminished the incidence of clinical renal disease (including prevention of recurrence in the renal transplant), and stabilized the glomerular filtration rate in patients with mild proteinuria. In the large series reported from Tel Hashomer Hospital in Israel, the rate of development of proteinuria at 9 to 11 years was 1.7 in 960 compliers versus 49 percent in 54 non-compliers [",
"    <a class=\"abstract\" href=\"UTD.htm?22/53/23383/abstract/19\">",
"     19",
"    </a>",
"    ]. In 86 patients who already had nonnephrotic proteinuria prior to therapy, colchicine led to resolution of proteinuria in five and to stabilization in 68. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/3/8247?source=see_link\">",
"     \"Management of familial Mediterranean fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among FMF patients with nephrotic syndrome due to AA amyloid, prevention of disease progression and a reduction in protein excretion can be achieved. However, a higher",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    dose of 1.5 to 2.0",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    appears to be required, and therapy should be instituted before the plasma creatinine concentration reaches 1.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (132",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/53/23383/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. Protein excretion in responders can be reduced to below 1 to 2",
"    <span class=\"nowrap\">",
"     grams/day",
"    </span>",
"    with this regimen; the benefit is gradual, occurring over a one- to two-year period [",
"    <a class=\"abstract\" href=\"UTD.htm?22/53/23383/abstract/20\">",
"     20",
"    </a>",
"    ]. A small number of patients do, however, appear to be resistant to the effects of colchicine, possibly reflecting genetic subsets of underlying disease or variable pharmacokinetics of the drug [",
"    <a class=\"abstract\" href=\"UTD.htm?22/53/23383/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     Colchicine",
"    </a>",
"    is not likely to be effective in FMF patients who already have chronic renal failure, since irreversible glomerular injury is probably present. However, it can prevent recurrent disease in the transplant [",
"    <a class=\"abstract\" href=\"UTD.htm?22/53/23383/abstract/21\">",
"     21",
"    </a>",
"    ]. The optimal colchicine dose in this setting is 1.5 to 2.0",
"    <span class=\"nowrap\">",
"     mg/day;",
"    </span>",
"    lower doses are less predictably effective. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/29/13784?source=see_link\">",
"     \"Renal amyloidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Anecdotal successes with chronic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    therapy (0.6 mg BID) have also been reported in patients with AA amyloid due to inflammatory bowel disease, in patients with Beh&ccedil;et&rsquo;s disease, and in intravenous drug users with suppurative skin lesions. Proteinuria due to renal amyloidosis may be markedly reduced, and renal function may remain stable over long periods of time [",
"    <a class=\"abstract\" href=\"UTD.htm?22/53/23383/abstract/22,24,25\">",
"     22,24,25",
"    </a>",
"    ]. However, repeat renal biopsy in one such patient did not demonstrate a reduction in total amyloid deposition despite almost complete resolution of proteinuria [",
"    <a class=\"abstract\" href=\"UTD.htm?22/53/23383/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is not clear whether the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    in some of these settings is related to a direct reduction in amyloid fibril production or to decreased activity of the primary disease (as may be the case in FMF, in which attacks may be associated with massive neutrophilic infiltration into affected tissues) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/53/23383/abstract/26\">",
"     26",
"    </a>",
"    ]. Regardless of the mechanism, colchicine must be continued indefinitely unless the underlying inflammatory disease can be corrected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Dimethylsulfoxide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/22/33123?source=see_link\">",
"     Dimethylsulfoxide",
"    </a>",
"    (DMSO) may have anti-amyloid activity in several forms of the disorder; it has been shown to be active in murine models of AA amyloidosis and in case reports of patients with AA amyloid due to rheumatoid arthritis or to Crohn&rsquo;s disease [",
"    <a class=\"abstract\" href=\"UTD.htm?22/53/23383/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. Use of DMSO is limited, however, by its acrid odor and, because of its potent solvent activity, by the difficulty attaining purity for pharmaceutical usage [",
"    <a class=\"abstract\" href=\"UTD.htm?22/53/23383/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Cytotoxic and immunosuppressive agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     Azathioprine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    have been shown to have activity against AA amyloid in individual case reports and small series. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A small retrospective study reported that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      may provide a significant survival benefit in patients with rheumatoid arthritis and renal AA amyloid [",
"      <a class=\"abstract\" href=\"UTD.htm?22/53/23383/abstract/16\">",
"       16",
"      </a>",
"      ]. In this study of 15 French patients, of whom six received monthly cyclophosphamide following confirmation of renal involvement, the survival of patients treated with pulse cyclophosphamide was longer than that of those administered non-alkylating drug regimens (mean survival of 165 and 46 months, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/53/23383/abstract/16\">",
"       16",
"      </a>",
"      ]. Trends toward decreased proteinuria and maintenance of renal function were also noted with cyclophosphamide.",
"     </li>",
"     <li>",
"      Similar results were confirmed in a cohort study reported from Japan [",
"      <a class=\"abstract\" href=\"UTD.htm?22/53/23383/abstract/11\">",
"       11",
"      </a>",
"      ]. Prospective studies are required to properly assess the role and toxicity of this agent in this setting.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Anticytokine therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increasing use of biologics with activities against proinflammatory cytokines (tumour necrosis factor-alpha and Interleukin-1) for diseases such as rheumatoid arthritis (RA) and ankylosing spondylitis may affect risk factors for the development of AA amyloid and may also be associated with reversal of established disease [",
"    <a class=\"abstract\" href=\"UTD.htm?22/53/23383/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    The majority of published experience that has shown efficacy has involved patients with RA and has reported on the first generation TNF-alpha antagonists (ie,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/53/23383/abstract/30,32,33\">",
"     30,32,33",
"    </a>",
"    ]. Less information is available regarding the newer TNF-alpha antagonists (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/6/39014?source=see_link\">",
"     certolizumab pegol",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35206?source=see_link\">",
"     golimumab",
"    </a>",
"    ) or other biologicals, such as abatecept and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    , which are effective in reducing disease activity but which do not have direct anticytokine activity.",
"   </p>",
"   <p>",
"    The effectiveness of the TNF antagonists appears, in part, to be directly related to their ability to lower serum SAA levels and may be enhanced by pulse therapy with glucocorticoids for induction [",
"    <a class=\"abstract\" href=\"UTD.htm?22/53/23383/abstract/34\">",
"     34",
"    </a>",
"    ]. This experience has been extended to AA amyloidosis complicating AS and Crohn&rsquo;s disease, with regression of tissue amyloid occurring as early as three months, documented by gastrointestinal biopsies in some instances [",
"    <a class=\"abstract\" href=\"UTD.htm?22/53/23383/abstract/35-37\">",
"     35-37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar efficacy has been reported for a humanized anti-IL-6 receptor antibody (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/19/44342?source=see_link\">",
"     tocilizumab",
"    </a>",
"    ) in improving AA amyloidosis complicating juvenile chronic polyarthritis and adult RA [",
"    <a class=\"abstract\" href=\"UTD.htm?22/53/23383/abstract/38-40\">",
"     38-40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The impact of anticytokine therapy in preventing AA amyloid in hereditary autoinflammatory diseases, such as familial Mediterranean fever (FMF), tumor necrosis factor receptor-associated periodic syndrome (TRAPS), or Muckle-Wells disease, is increasingly clear. AA amyloidosis may complicate conditions related to pyrin mutations (in particular, homozygosity for the 694V), with and without the phenotype of FMF, TRAPS, the full spectrum of cryopyrinopathies (familial cold autoinflammatory syndrome, which is also termed familial cold urticaria; Muckle-Wells syndrome; and neonatal onset multisystem inflammatory disorder), and hyperimmunoglobulinemia D, with varying incidences depending upon disease and ethnic background [",
"    <a class=\"abstract\" href=\"UTD.htm?22/53/23383/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The bulk of experience has focused on the central role of the NALP3 inflammasome, on the aberrant function in the cryopyrinopathies, and on the efficacy of a commercially available IL-1-receptor antagonist,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/294?source=see_link\">",
"     anakinra",
"    </a>",
"    , in attenuating both disease and resulting amyloid [",
"    <a class=\"abstract\" href=\"UTD.htm?22/53/23383/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. No information is available regarding the potential efficacy for AA amyloidosis of other synthetic (eg, caspase 1 inhibitors) or biologic (eg, monoclonal anti-IL-1 antibodies or IL-1 TRAP) agents that are effective in reducing cryopyrinopathy disease manifestations. With regard to TRAPS and FMF, both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    and anakinra have been reported as effective treatments for disease manifestations and for lowering of SAA levels [",
"    <a class=\"abstract\" href=\"UTD.htm?22/53/23383/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. However, similar efficacy to that seen with etanercept has not been obtained with use of other TNF inhibitors,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    , in patients with TRAPS [",
"    <a class=\"abstract\" href=\"UTD.htm?22/53/23383/abstract/41\">",
"     41",
"    </a>",
"    ], and whether these agents are effective for preventing or reversing AA amyloidosis has not been described.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Investigational approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Accumulating knowledge regarding the structural basis of fibrillogenesis has stimulated alternative approaches to therapy. Sometimes referred to as akin to putting &ldquo;sand in the (beta) sheets,&rdquo; they include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Design of or search for ligands that stabilize the native conformation of subunit proteins",
"     </li>",
"     <li>",
"      Development of agents that interfere with binding to cofactors",
"     </li>",
"     <li>",
"      Development of drugs that inhibit the adoption of the beta-pleated sheet configuration (either generically or specifically to the type of amyloid)",
"     </li>",
"     <li>",
"      Use of chaperones to reverse aggregation",
"     </li>",
"     <li>",
"      Alterations of the milieu that is responsible for off-pathway aggregation",
"     </li>",
"     <li>",
"      Development of methods to stimulate resorption of amyloid from tissue",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    New classes of agents may eventually prove efficacious by interfering with fibril formation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/53/23383/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. Low molecular weight (mw) anionic sulfonates or sulfates, as well as low mw heparins, impede AA fibril formation in vitro and attenuate the development of murine AA amyloid [",
"    <a class=\"abstract\" href=\"UTD.htm?22/53/23383/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. This hypothesis was tested in a randomized, multicenter international phase",
"    <span class=\"nowrap\">",
"     II/III",
"    </span>",
"    trial of the first of these compounds (eprodisate) for the treatment of 150 patients with AA amyloid [",
"    <a class=\"abstract\" href=\"UTD.htm?22/53/23383/abstract/50\">",
"     50",
"    </a>",
"    ]. In this study, eprodisate showed a clinical benefit in delaying the decline in renal function for AA amyloidosis patients, defined as a reduction in risk and delayed time to doubling of serum creatinine, to 50 percent decrease in creatinine clearance, or to progression to dialysis, end-stage renal disease, or death (from all causes). This finding was amplified in an open-label extension that reported reduction in the rate of renal decline when patients initially treated under placebo for two years were switched to eprodisate for a year.",
"   </p>",
"   <p>",
"    Other studies have examined the potential efficacy of novel compounds that affect glycosaminoglycan biosynthesis and that retard the development of AA amyloid in experimental models [",
"    <a class=\"abstract\" href=\"UTD.htm?22/53/23383/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Animal models",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of agents appear to retard murine AA amyloidosis. These include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/22/33123?source=see_link\">",
"     dimethylsulfoxide",
"    </a>",
"    , inhibition of interactions between SAA and the receptor for advanced glycation end-products (RAGE),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/23/17784?source=see_link\">",
"     fenofibrate",
"    </a>",
"    , FK506, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/20/42312?source=see_link\">",
"     lovastatin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/53/23383/abstract/52-54\">",
"     52-54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to the agents mentioned above, a novel bis (proline) compound (CPHPC) has been developed that binds with high affinity to serum amyloid P component (SAP) binding to amyloid fibrils, resulting in rapid clearance of SAP by the liver and depleting its serum level by approximately 90 percent. In a preliminary report, this resulted in disappearance of deposits in three types of systemic amyloidosis (AL, ATTR, and AA), as assessed by SAP scintigraphy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/53/23383/abstract/55\">",
"     55",
"    </a>",
"    ]. This effect was sustained in follow-up studies [",
"    <a class=\"abstract\" href=\"UTD.htm?22/53/23383/abstract/56\">",
"     56",
"    </a>",
"    ]; however, approximately 20 percent of P-component remained associated with the amyloid deposits, which were only slowly resorbed.",
"   </p>",
"   <p>",
"    In a murine model for AA amyloid, SAP depletion following CPHPC was then followed with treatment using polyclonal anti-SAP, resulting in a rapid complement-dependent, macrophage-derived giant cell reaction which appeared to clear visceral amyloid deposits [",
"    <a class=\"abstract\" href=\"UTD.htm?22/53/23383/abstract/57\">",
"     57",
"    </a>",
"    ]. This proof-of-concept study may provide a new and generic therapeutic approach to the treatment of systemic and possibly localized forms of amyloidosis.",
"   </p>",
"   <p>",
"    Another novel approach to the treatment of AA amyloidosis may be to utilize antisense oligonucleotides to knock down the mRNA for SAA; this approach has been effective in attenuating amyloid deposition in the murine model [",
"    <a class=\"abstract\" href=\"UTD.htm?22/53/23383/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H105984589\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In untreated patients, secondary (AA) amyloidosis has a significant degree of mortality due to end-stage renal disease, infection, heart failure, bowel perforation, or gastrointestinal bleeding. Patients with persistently high circulating levels of SAA are at particular risk of these complications of disease. Other adverse prognostic signs included older age, reduced serum albumin concentration, and end-stage renal failure at baseline. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Successful treatment of the underlying inflammatory process can lead to stabilization of or improvement in renal function, to reduction in protein excretion, and to partial resolution of amyloid deposits. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Importance of control of the underlying disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The preferred therapy of AA amyloid is control of the underlying inflammatory disease.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"       Colchicine",
"      </a>",
"      has become accepted therapy for prophylaxis and treatment of secondary amyloidosis, particularly in familial Mediterranean fever, and anti-proinflammatory cytokines (IL-1&beta;, TNF-&alpha;, IL-6) have been shown to have efficacy in some cases of AA amyloidosis due to rheumatic disorders and to hereditary autoinflammatory disease. Agents under development interfere with fibril formation. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Treatment of AA amyloidosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23383/abstract/1\">",
"      Pettersson T, Konttinen YT, Maury CP. Treatment strategies for amyloid A amyloidosis. Expert Opin Pharmacother 2008; 9:2117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23383/abstract/2\">",
"      Obici L, Raimondi S, Lavatelli F, et al. Susceptibility to AA amyloidosis in rheumatic diseases: a critical overview. Arthritis Rheum 2009; 61:1435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23383/abstract/3\">",
"      Lachmann HJ, Goodman HJ, Gilbertson JA, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med 2007; 356:2361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23383/abstract/4\">",
"      Tanaka F, Migita K, Honda S, et al. Clinical outcome and survival of secondary (AA) amyloidosis. Clin Exp Rheumatol 2003; 21:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23383/abstract/5\">",
"      Falck HM, Maury CP, Teppo AM, Wegelius O. Correlation of persistently high serum amyloid A protein and C-reactive protein concentrations with rapid progression of secondary amyloidosis. Br Med J (Clin Res Ed) 1983; 286:1391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23383/abstract/6\">",
"      Berglund K, Thysell H, Keller C. Results, principles and pitfalls in the management of renal AA-amyloidosis; a 10-21 year followup of 16 patients with rheumatic disease treated with alkylating cytostatics. J Rheumatol 1993; 20:2051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23383/abstract/7\">",
"      Lovat LB, Madhoo S, Pepys MB, Hawkins PN. Long-term survival in systemic amyloid A amyloidosis complicating Crohn's disease. Gastroenterology 1997; 112:1362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23383/abstract/8\">",
"      Waldenstr&ouml;m H. On the formation and disappearance of amyloid in man. Acta Chir Scand 1928; 63:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23383/abstract/9\">",
"      Shimojima Y, Takei Y, Tazawa K, et al. Histopathological regression of systemic AA amyloidosis after surgical treatment of a localized Castleman's disease. Amyloid 2006; 13:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23383/abstract/10\">",
"      Ortiz-Santamar&iacute;a V, Oliv&eacute; A, Valls-Roc M, Tena X. Treatment of AA amyloid with chlorambucil. Rheumatology (Oxford) 2002; 41:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23383/abstract/11\">",
"      Nakamura T, Yamamura Y, Tomoda K, et al. Efficacy of cyclophosphamide combined with prednisolone in patients with AA amyloidosis secondary to rheumatoid arthritis. Clin Rheumatol 2003; 22:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23383/abstract/12\">",
"      Mpofu S, Teh LS, Smith PJ, et al. Cytostatic therapy for AA amyloidosis complicating psoriatic spondyloarthropathy. Rheumatology (Oxford) 2003; 42:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23383/abstract/13\">",
"      Gillmore JD, Lovat LB, Persey MR, et al. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet 2001; 358:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23383/abstract/14\">",
"      Hawkins PN, Richardson S, Vigushin DM, et al. Serum amyloid P component scintigraphy and turnover studies for diagnosis and quantitative monitoring of AA amyloidosis in juvenile rheumatoid arthritis. Arthritis Rheum 1993; 36:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23383/abstract/15\">",
"      Desch&ecirc;nes G, Prieur AM, Hayem F, et al. Renal amyloidosis in juvenile chronic arthritis: evolution after chlorambucil treatment. Pediatr Nephrol 1990; 4:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23383/abstract/16\">",
"      Chevrel G, Jenvrin C, McGregor B, Miossec P. Renal type AA amyloidosis associated with rheumatoid arthritis: a cohort study showing improved survival on treatment with pulse cyclophosphamide. Rheumatology (Oxford) 2001; 40:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23383/abstract/17\">",
"      Lachmann HJ, Gilbertson JA, Gillmore JD, et al. Unicentric Castleman's disease complicated by systemic AA amyloidosis: a curable disease. QJM 2002; 95:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23383/abstract/18\">",
"      Livneh A, Zemer D, Langevitz P, et al. Colchicine in the treatment of AA and AL amyloidosis. Semin Arthritis Rheum 1993; 23:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23383/abstract/19\">",
"      Zemer D, Pras M, Sohar E, et al. Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever. N Engl J Med 1986; 314:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23383/abstract/20\">",
"      Livneh A, Zemer D, Langevitz P, et al. Colchicine treatment of AA amyloidosis of familial Mediterranean fever. An analysis of factors affecting outcome. Arthritis Rheum 1994; 37:1804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23383/abstract/21\">",
"      Livneh A, Zemer D, Siegal B, et al. Colchicine prevents kidney transplant amyloidosis in familial Mediterranean fever. Nephron 1992; 60:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23383/abstract/22\">",
"      Greenstein AJ, Sachar DB, Panday AK, et al. Amyloidosis and inflammatory bowel disease. A 50-year experience with 25 patients. Medicine (Baltimore) 1992; 71:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23383/abstract/23\">",
"      Lidar M, Scherrmann JM, Shinar Y, et al. Colchicine nonresponsiveness in familial Mediterranean fever: clinical, genetic, pharmacokinetic, and socioeconomic characterization. Semin Arthritis Rheum 2004; 33:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23383/abstract/24\">",
"      Tasdemir I, Sivri B, Turgan C, et al. The expanding spectrum of a disease. Beh&ccedil;et's disease associated with amyloidosis. Nephron 1989; 52:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23383/abstract/25\">",
"      Tan AU Jr, Cohen AH, Levine BS. Renal amyloidosis in a drug abuser. J Am Soc Nephrol 1995; 5:1653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23383/abstract/26\">",
"      Cerquaglia C, Diaco M, Nucera G, et al. Pharmacological and clinical basis of treatment of Familial Mediterranean Fever (FMF) with colchicine or analogues: an update. Curr Drug Targets Inflamm Allergy 2005; 4:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23383/abstract/27\">",
"      Iwakiri R, Sakemi T, Fujimoto K. Dimethylsulfoxide for renal dysfunction caused by systemic amyloidosis complicating Crohn's disease. Gastroenterology 1999; 117:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23383/abstract/28\">",
"      Amemori S, Iwakiri R, Endo H, et al. Oral dimethyl sulfoxide for systemic amyloid A amyloidosis complication in chronic inflammatory disease: a retrospective patient chart review. J Gastroenterol 2006; 41:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23383/abstract/29\">",
"      Jimenez RA, Willkens RF. Dimethyl sulfoxide: a perspective of its use in rheumatic diseases. J Lab Clin Med 1982; 100:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23383/abstract/30\">",
"      Gottenberg JE, Merle-Vincent F, Bentaberry F, et al. Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacy. Arthritis Rheum 2003; 48:2019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23383/abstract/31\">",
"      Fern&aacute;ndez-Nebro A, Tomero E, Ortiz-Santamar&iacute;a V, et al. Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists. Am J Med 2005; 118:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23383/abstract/32\">",
"      Nakamura T, Higashi S, Tomoda K, et al. Etanercept can induce resolution of renal deterioration in patients with amyloid A amyloidosis secondary to rheumatoid arthritis. Clin Rheumatol 2010; 29:1395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23383/abstract/33\">",
"      Keersmaekers T, Claes K, Kuypers DR, et al. Long-term efficacy of infliximab treatment for AA-amyloidosis secondary to chronic inflammatory arthritis. Ann Rheum Dis 2009; 68:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23383/abstract/34\">",
"      Perry ME, Stirling A, Hunter JA. Effect of etanercept on serum amyloid A protein (SAA) levels in patients with AA amyloidosis complicating inflammatory arthritis. Clin Rheumatol 2008; 27:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23383/abstract/35\">",
"      Park YK, Han DS, Eun CS. Systemic amyloidosis with Crohn's disease treated with infliximab. Inflamm Bowel Dis 2008; 14:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23383/abstract/36\">",
"      Kobak S, Oksel F, Kabasakal Y, Doganavsargil E. Ankylosing spondylitis-related secondary amyloidosis responded well to etanercept: a report of three patients. Clin Rheumatol 2007; 26:2191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23383/abstract/37\">",
"      Kuroda T, Wada Y, Kobayashi D, et al. Effective anti-TNF-alpha therapy can induce rapid resolution and sustained decrease of gastroduodenal mucosal amyloid deposits in reactive amyloidosis associated with rheumatoid arthritis. J Rheumatol 2009; 36:2409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23383/abstract/38\">",
"      Okuda Y, Takasugi K. Successful use of a humanized anti-interleukin-6 receptor antibody, tocilizumab, to treat amyloid A amyloidosis complicating juvenile idiopathic arthritis. Arthritis Rheum 2006; 54:2997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23383/abstract/39\">",
"      Nishida S, Hagihara K, Shima Y, et al. Rapid improvement of AA amyloidosis with humanised anti-interleukin 6 receptor antibody treatment. Ann Rheum Dis 2009; 68:1235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23383/abstract/40\">",
"      Inoue D, Arima H, Kawanami C, et al. Excellent therapeutic effect of tocilizumab on intestinal amyloid a deposition secondary to active rheumatoid arthritis. Clin Rheumatol 2010; 29:1195.",
"     </a>",
"    </li>",
"    <li>",
"     Ombrello AK. Modern therapies in AA amyloidosis. In: Amyloid and Related Disorders: Surgical Pathology and Clinical Correlations, Picken MM, Dogan A, Herrera GA.  (Eds), Humana Press, New York 2012. p.399.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23383/abstract/42\">",
"      Leslie KS, Lachmann HJ, Bruning E, et al. Phenotype, genotype, and sustained response to anakinra in 22 patients with autoinflammatory disease associated with CIAS-1/NALP3 mutations. Arch Dermatol 2006; 142:1591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23383/abstract/43\">",
"      Thornton BD, Hoffman HM, Bhat A, Don BR. Successful treatment of renal amyloidosis due to familial cold autoinflammatory syndrome using an interleukin 1 receptor antagonist. Am J Kidney Dis 2007; 49:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23383/abstract/44\">",
"      Gattorno M, Pelagatti MA, Meini A, et al. Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum 2008; 58:1516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23383/abstract/45\">",
"      Moser C, Pohl G, Haslinger I, et al. Successful treatment of familial Mediterranean fever with Anakinra and outcome after renal transplantation. Nephrol Dial Transplant 2009; 24:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23383/abstract/46\">",
"      Gillmore JD, Hawkins PN. Drug Insight: emerging therapies for amyloidosis. Nat Clin Pract Nephrol 2006; 2:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23383/abstract/47\">",
"      Gazit E. Mechanisms of amyloid fibril self-assembly and inhibition. Model short peptides as a key research tool. FEBS J 2005; 272:5971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23383/abstract/48\">",
"      Kisilevsky R, Lemieux LJ, Fraser PE, et al. Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: implications for Alzheimer's disease. Nat Med 1995; 1:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23383/abstract/49\">",
"      Zhu H, Yu J, Kindy MS. Inhibition of amyloidosis using low-molecular-weight heparins. Mol Med 2001; 7:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23383/abstract/50\">",
"      Dember LM, Hawkins PN, Hazenberg BP, et al. Eprodisate for the treatment of renal disease in AA amyloidosis. N Engl J Med 2007; 356:2349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23383/abstract/51\">",
"      Kisilevsky R, Szarek WA, Ancsin J, et al. Novel glycosaminoglycan precursors as anti-amyloid agents, part III. J Mol Neurosci 2003; 20:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23383/abstract/52\">",
"      Yan SD, Zhu H, Zhu A, et al. Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis. Nat Med 2000; 6:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23383/abstract/53\">",
"      Ueda M, Ando Y, Nakamura M, et al. FK506 inhibits murine AA amyloidosis: possible involvement of T cells in amyloidogenesis. J Rheumatol 2006; 33:2260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23383/abstract/54\">",
"      van der Hilst JC, Kluve-Beckerman B, Bodar EJ, et al. Lovastatin inhibits formation of AA amyloid. J Leukoc Biol 2008; 83:1295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23383/abstract/55\">",
"      Pepys MB, Herbert J, Hutchinson WL, et al. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature 2002; 417:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23383/abstract/56\">",
"      Gillmore JD, Tennent GA, Hutchinson WL, et al. Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis. Br J Haematol 2010; 148:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23383/abstract/57\">",
"      Bodin K, Ellmerich S, Kahan MC, et al. Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature 2010; 468:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23383/abstract/58\">",
"      Kluve-Beckerman B, Du L, Benson MD. AA amyloidosis: potential therapy with antisense oligonucleotides. Amyloid 2011; 18 Suppl 1:200.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5588 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-41.78.124.10-207A0925F2-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_53_23383=[""].join("\n");
var outline_f22_53_23383=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H105984589\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Importance of control of the underlying disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      TREATMENT OF AA AMYLOIDOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Colchicine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Dimethylsulfoxide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Cytotoxic and immunosuppressive agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Anticytokine therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Investigational approaches",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Animal models",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H105984589\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/3/8247?source=related_link\">",
"      Management of familial Mediterranean fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30086?source=related_link\">",
"      Pathogenesis of secondary (AA) amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/29/13784?source=related_link\">",
"      Renal amyloidosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_53_23384="Fluticasone and salmeterol: Pediatric drug information";
var content_f22_53_23384=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Fluticasone and salmeterol: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?25/33/26136?source=see_link\">",
"    see \"Fluticasone and salmeterol: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?8/16/8454?source=see_link\">",
"    see \"Fluticasone and salmeterol: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708807\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F173432\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Advair Diskus&reg;;",
"     </li>",
"     <li>",
"      Advair&reg; HFA",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F173433\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Advair Diskus&reg;;",
"     </li>",
"     <li>",
"      Advair&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1058776\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Adrenal Corticosteroid",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Adrenergic Agonist Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anti-inflammatory Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiasthmatic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Beta",
"       <sub>",
"        2",
"       </sub>",
"       -Adrenergic Agonist",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Bronchodilator",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Corticosteroid, Inhalant (Oral)",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Glucocorticoid",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1058769\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?25/33/26136?source=see_link\">",
"      see \"Fluticasone and salmeterol: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Asthma, maintenance treatment:",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Titrate dosage to the lowest effective strength which maintains control of asthma. Dose may be increased after 2 weeks if patient does not respond adequately.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral powder for inhalation: Advair Diskus&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 4-11 years without prior inhaled corticosteroid: Fluticasone 100 mcg/salmeterol 50 mcg (Advair&trade; Diskus&reg; 100/50) 1 inhalation twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &ge;12 years and Adults without prior inhaled corticosteroid: Fluticasone 100 mcg/salmeterol 50 mcg (Advair&trade; Diskus&reg; 100/50) 1 inhalation twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &ge;12 years and Adults currently receiving an inhaled corticosteroid: The starting dose is dependent upon the current steroid therapy, see table.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Oral inhalation: Metered dose inhaler: Advair&reg; HFA:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children &ge;12 years and Adults without prior inhaled corticosteroid: 2 inhalations twice daily of either fluticasone 45 mcg/salmeterol 21 mcg (Advair&reg; HFA 45/21) or fluticasone 115 mcg/salmeterol 21 mcg (Advair&reg; HFA 115/21); not to exceed 2 inhalations twice daily of fluticasone 230 mcg/salmeterol 21 mcg (Advair&reg; HFA 230/21)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children &ge;12 years and Adults currently receiving an inhaled corticosteroid: The starting dose is dependent upon the current steroid therapy; see table. Not to exceed 2 inhalations twice daily of fluticasone 230 mcg/salmeterol 21 mcg (Advair&reg; HFA 230/21)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      COPD, maintenance treatment:",
"     </b>",
"     Oral powder for inhalation: Advair Diskus&reg;: Adults: Fluticasone 250 mcg/salmeterol 50 mcg (Advair Diskus&reg; 250/50) 1 inhalation twice daily",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Recommended Starting Dose of Fluticasone / Salmeterol (Advair Diskus&reg;) for Patients Currently Taking",
"      <b>",
"       <span style=\"text-decoration: underline\">",
"        Inhaled Corticosteroids",
"       </span>",
"      </b>",
"     </caption>",
"     <col align=\"left\" width=\"200\">",
"     </col>",
"     <col align=\"center\" width=\"130\">",
"     </col>",
"     <col align=\"center\" width=\"130\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\" colspan=\"2\">",
"        <p style=\"text-indent:0em;\">",
"         Current Daily Dose of",
"         <span style=\"text-decoration: underline\">",
"          Inhaled",
"         </span>",
"         Corticosteroid",
"         <sup>",
"          1",
"         </sup>",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Advair Diskus&reg;",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         1 inhalation twice daily",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tfoot valign=\"middle\">",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          1",
"         </sup>",
"         Not for use in patients transferring from systemic corticosteroid therapy",
"        </p>",
"       </td>",
"      </tr>",
"     </tfoot>",
"     <tbody valign=\"top\">",
"      <tr>",
"       <td align=\"left\" rowspan=\"3\">",
"        <p style=\"text-indent:0em;\">",
"         Beclomethasone dipropionate HFA inhalation aerosal",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         160 mcg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         100/50",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         320 mcg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250/50",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         640 mcg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         500/50",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" rowspan=\"3\">",
"        <p style=\"text-indent:0em;\">",
"         Budesonide inhalation aerosal",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &le;400 mcg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         100/50",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         800-1200 mcg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250/50",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1600 mcg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         500/50",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" rowspan=\"2\">",
"        <p style=\"text-indent:0em;\">",
"         Flunisolide inhalation aerosal",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &le;1000 mcg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         100/50",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1250-2000 mcg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250/50",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" rowspan=\"2\">",
"        <p style=\"text-indent:0em;\">",
"         Flunisolide HFA inhalation aerosal",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &le;320 mcg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         100/50",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         640 mcg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250/50",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" rowspan=\"3\">",
"        <p style=\"text-indent:0em;\">",
"         Fluticasone propionate HFA inhalation aerosol",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &le;176 mcg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         100/50",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         440 mcg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250/50",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         660-880 mcg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         500/50",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" rowspan=\"3\">",
"        <p style=\"text-indent:0em;\">",
"         Fluticasone propionate inhalation powder",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &le;200 mcg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         100/50",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         500 mcg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250/50",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1000 mcg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         500/50",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" rowspan=\"3\">",
"        <p style=\"text-indent:0em;\">",
"         Mometasone furoate inhalation powder",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         220 mcg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         100/50",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         440 mcg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250/50",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         880 mcg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         500/50",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" rowspan=\"2\">",
"        <p style=\"text-indent:0em;\">",
"         Triamcinolone acetate inhalation aerosal",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &le;1000 mcg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         100/50",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1100-1600 mcg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250/50",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Recommended Starting Dose of Fluticasone / Salmeterol (Advair&reg; HFA) for Patients Currently Taking",
"      <b>",
"       <span style=\"text-decoration: underline\">",
"        Inhaled Corticosteroids",
"       </span>",
"      </b>",
"     </caption>",
"     <col align=\"left\" width=\"200\">",
"     </col>",
"     <col align=\"center\" width=\"130\">",
"     </col>",
"     <col align=\"center\" width=\"130\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\" colspan=\"2\">",
"        <p style=\"text-indent:0em;\">",
"         Current Daily Dose of",
"         <span style=\"text-decoration: underline\">",
"          Inhaled",
"         </span>",
"         Corticosteroid",
"         <sup>",
"          1",
"         </sup>",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Advair&reg; HFA",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         2 inhalations twice daily",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tfoot valign=\"middle\">",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          1",
"         </sup>",
"         Not for use in patients transferring from systemic corticosteroid therapy",
"        </p>",
"       </td>",
"      </tr>",
"     </tfoot>",
"     <tbody valign=\"top\">",
"      <tr>",
"       <td align=\"left\" rowspan=\"3\">",
"        <p style=\"text-indent:0em;\">",
"         Beclomethasone dipropionate HFA inhalation aerosal",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &le;160 mcg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         45/21",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         320 mcg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         115/21",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         640 mcg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         230/21",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" rowspan=\"3\">",
"        <p style=\"text-indent:0em;\">",
"         Budesonide inhalation powder",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &le;400 mcg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         45/21",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         800-1200 mcg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         115/21",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1600 mcg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         230/21",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" rowspan=\"2\">",
"        <p style=\"text-indent:0em;\">",
"         Flunisolide CFC inhalation aerosal",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &le;1000 mcg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         45/21",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1250-2000 mcg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         115/21",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" rowspan=\"2\">",
"        <p style=\"text-indent:0em;\">",
"         Flunisolide HFA inhalation aerosal",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &le;320 mcg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         45/21",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         640 mcg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         115/21",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" rowspan=\"3\">",
"        <p style=\"text-indent:0em;\">",
"         Fluticasone propionate HFA inhalation aerosol",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &le;176 mcg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         45/21",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         440 mcg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         115/21",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         660-880 mcg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         230/21",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" rowspan=\"3\">",
"        <p style=\"text-indent:0em;\">",
"         Fluticasone propionate inhalation powder",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &le;200 mcg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         45/21",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         500 mcg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         115/21",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1000 mcg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         230/21",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" rowspan=\"3\">",
"        <p style=\"text-indent:0em;\">",
"         Mometasone furoate inhalation powder",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         220 mcg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         45/21",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         440 mcg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         115/21",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         880 mcg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         230/21",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" rowspan=\"2\">",
"        <p style=\"text-indent:0em;\">",
"         Triamcinolone acetonide inhalation aerosal",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &le;1000 mcg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         45/21",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1100-1600 mcg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         115/21",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F173414\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Aerosol, for oral inhalation:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Advair&reg; HFA:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     45/21: Fluticasone propionate 45 mcg and salmeterol 21 mcg per inhalation (8 g) [chlorofluorocarbon free; 60 metered actuations]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     45/21: Fluticasone propionate 45 mcg and salmeterol 21 mcg per inhalation (12 g) [chlorofluorocarbon free; 120 metered actuations]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     115/21: Fluticasone propionate 115 mcg and salmeterol 21 mcg per inhalation (8 g) [chlorofluorocarbon free; 60 metered actuations]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     115/21: Fluticasone propionate 115 mcg and salmeterol 21 mcg per inhalation (12 g) [chlorofluorocarbon free; 120 metered actuations]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     230/21: Fluticasone propionate 230 mcg and salmeterol 21 mcg per inhalation (8 g) [chlorofluorocarbon free; 60 metered actuations]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     230/21: Fluticasone propionate 230 mcg and salmeterol 21 mcg per inhalation (12 g) [chlorofluorocarbon free; 120 metered actuations]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder, for oral inhalation:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Advair Diskus&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     100/50: Fluticasone propionate 100 mcg and salmeterol 50 mcg (14s, 28s [DSC], 60s) [contains lactose]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     250/50: Fluticasone propionate 250 mcg and salmeterol 50 mcg (14s [DSC], 60s) [contains lactose]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     500/50: Fluticasone propionate 500 mcg and salmeterol 50 mcg (14s [DSC], 60s) [contains lactose]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F173400\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874505\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Advair Diskus&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm111326.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm111326.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Advair&reg; HFA:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm111333.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm111333.pdf",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1058780\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral inhalation:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Advair Diskus&reg;, powder for oral inhalation: A device containing a double-foil blister of a powder formulation for oral inhalation; each blister contains 1 complete dose of both medications;  the medication is opened by activating the device, dispersed into the airstream created by the patient inhaling through the mouthpiece; it may not be used with a spacer. Follow the patient directions for use which are provided with each device; do not exhale into the Diskus&reg; or attempt to take it apart. Always activate and use the Diskus&reg; in a level, horizontal position. Do not wash the mouthpiece or any part of the Diskus&reg;; it must be kept dry.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Advair&reg; HFA, metered dose inhalation: Prime before using the first time by releasing 4 test sprays into the air away from the face, shaking well for 5 seconds before each spray. Reprime with 2 test sprays if the inhaler has been dropped or not used for more than 4 weeks; discard after 120 actuations. Never immerse canister into water. Shake well for 5 seconds before using.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1058772\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Advair Diskus&reg;: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Store in a dry place out of direct heat or sunlight. Discard device 1 month after removal from  foil  pouch or when the dose indicator reads &ldquo;0&rdquo; (whichever comes first); device is not reusable.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Advair&reg; HFA: Store at controlled room temperature of 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Do not expose to temperatures &gt;120&deg;F; do not puncture or incinerate. Store with mouthpiece down. When the counter reads \"000,\" discard device.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1058779\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Advair Diskus&reg;, Advair&reg; HFA: Maintenance treatment of asthma (Advair Diskus&reg;: FDA approved in ages &ge;4 years and adults; Advair&reg; HFA: FDA approved in ages &ge;12 years and adults);",
"     <b>",
"      NOT",
"     </b>",
"     indicated for the relief of acute bronchospasm",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Advair Diskus&reg;: Maintenance treatment of airflow obstruction in patients with COPD associated with chronic bronchitis and emphysema (FDA approved in adults);",
"     <b>",
"      NOT",
"     </b>",
"     indicated for the relief of acute bronchospasm",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F173461\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Advair&reg; may be confused with Adcirca&reg;, Advicor&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F173458\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Arrhythmia, chest symptoms, fluid retention, MI, palpitation, syncope, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Compressed nerve syndromes, dizziness, headache, hypnagogic effects, migraine, pain, sleep disorders, tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Dermatitis, dermatosis, eczema, hives, skin flakiness, urticaria, viral skin infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypothyroidism, menstruation symptoms",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Constipation, dental discomfort/pain, diarrhea, gastrointestinal infection, GI pain/discomfort, hemorrhoids, nausea, oral candidiasis, oral discomfort/pain, oral erythema/rash, oral ulcerations, unusual taste, viral GI infection, vomiting, weight gain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Contusions/hematomas",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Abnormal liver function test",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, articular rheumatism, bone/cartilage disorders, bone pain, cramps, fractures, muscle injuries, muscle pain, muscle spasm, muscle stiffness, musculoskeletal pain, tightness/rigidity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Conjunctivitis, edema, eye redness, keratitis, xerophthalmia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Blood in nasal mucosa, bronchitis, congestion, cough, dysphonia, ear/nose/throat infection, epistaxis, hoarseness, laryngitis, lower respiratory hemorrhage, lower respiratory tract infection, nasal irritation, pneumonia, rhinitis, rhinorrhea/postnasal drip, sinusitis, sneezing, throat irritation, upper respiratory tract infection, upper respiratory tract inflammation, viral respiratory tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergies/allergic reactions, bacterial infection, burns, candidiasis, diaphoresis, sweat/sebum disorders, viral infection, wounds and lacerations",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Asthma exacerbation (serious and some fatal), abdominal pain, agitation, aggression, anaphylactic reaction (some in patients with severe milk allergy [Diskus&reg;]), angioedema, aphonia, atrial fibrillation, bronchospasm, cataracts, chest congestion, chest tightness, choking, contact dermatitis, Cushing syndrome, Cushingoid features, depression, dysmenorrhea, dyspepsia, dyspnea, earache, ecchymoses, edema (facial, oropharyngeal), eosinophilic conditions, glaucoma, growth velocity reduction in children/adolescents, hyperactivity, hypercorticism, hyperglycemia, hypersensitivity reaction (immediate and delayed), hypertension, hypokalemia, hypothyroidism, influenza, intraocular pressure increased, irritability, laryngeal spasm/irritation, irregular menstruation, myositis, osteoporosis, pallor, paresthesia, paradoxical tracheitis, paranasal sinus pain, photodermatitis, PID, rash, restlessness, stridor, supraventricular tachycardia, syncope, vaginal candidiasis, vaginitis, vulvovaginitis, rare cases of vasculitis (Churg-Strauss syndrome), ventricular tachycardia, wheezing, xerostomia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1058784\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to salmeterol, adrenergic amines, fluticasone, or any component; severe hypersensitivity to milk proteins (Advair Diskus&reg;); primary treatment of status asthmaticus or other acute episodes of asthma or COPD",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1058768\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with cardiovascular disorders (especially coronary insufficiency, arrhythmias, hypertension, heart failure); although uncommon at recommended doses, beta-agonists may cause elevation in BP and HR and result in CNS stimulation and excitation. Caution should also be used in patients with thyrotoxicosis, seizure  disorders, or conditions that are unusually sensitive to the effects of sympathomimetic amines. Transient hypokalemia from intracellular shunting may occur and produce adverse cardiovascular effects. Use with caution in patients with diabetes mellitus (DM); beta",
"     <sub>",
"      2",
"     </sub>",
"     -agonists can increase serum glucose aggravating pre-existing DM and ketoacidosis. Use caution in patients with hepatic impairment. Immediate hypersensitivity reactions (urticaria, angioedema, rash, bronchospasm) have been reported. Powder for oral inhalation (Advair Diskus&reg;) contains lactose; very rare anaphylactic reactions have been reported in patients with severe milk protein allergy.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Suppression of HPA function, suppression of linear growth (ie, reduction of growth velocity), reduced bone mineral density or hypercorticism (Cushing's syndrome) may occur; titrate to lowest effective dose. Reduction in growth velocity [mean: 1 cm/year (range: 0.3-1.8 cm)] may occur when corticosteroids are administered to pediatric patients, even at recommended doses via inhaled route; related to dose and duration of exposure; monitor growth. Use with extreme caution in patients with respiratory tuberculosis, untreated systemic infections, or ocular herpes simplex. Rare cases of increased IOP, glaucoma, or cataracts have been reported with inhaled corticosteroids, including fluticasone. Pneumonia and other lower respiratory tract infections have been reported in patients with COPD following the use of inhaled corticosteroids; monitor COPD patients closely since pneumonia symptoms may overlap symptoms of exacerbations.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1058767\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Long-acting beta",
"     <sub>",
"      2",
"     </sub>",
"     -adrenergic agents (LABAs), including salmeterol, increase the risk of asthma-related deaths",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Fluticasone and salmeterol should only be prescribed in patients not adequately controlled on long-term asthma-controller medications (ie, inhaled corticosteroid) or disease severity requires initiation with two maintenance therapies. In a large clinical trial, LABA (salmeterol) use was associated with an increase in asthma-related deaths compared to placebo (when added to usual asthma therapy); risk is considered a class effect among all LABAs. Data are not available to determine if the addition of an inhaled corticosteroid lessens this increased risk of death associated with LABA use or if LABA use also increases the risk of death in patients with COPD. Assess patients at regular intervals once asthma control is maintained on combination therapy to determine if step down therapy is appropriate (without loss of asthma control), and if the patient can be maintained on an inhaled corticosteroid alone. LABAs are not appropriate in patients whose asthma is adequately controlled on low- or medium-dose inhaled corticosteroids. LABAs may increase the risk of asthma-related hospitalization in pediatric and adolescent patients",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; when addition of a LABA is clinically indicated in patients &lt;18 years of age, a combination product containing a LABA and an inhaled corticosteroid is preferred to ensure compliance.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Fluticasone and salmeterol should not be used to relieve acute asthmatic or COPD symptoms, rapidly deteriorating or potentially life-threatening episodes of asthma or COPD; acute episodes should be treated with short-acting beta",
"     <sub>",
"      2",
"     </sub>",
"     -agonist. Routine use of inhaled, short-acting beta",
"     <sub>",
"      2",
"     </sub>",
"     -agonists should be discontinued prior to initiation of fluticasone and salmeterol. Fluticasone and salmeterol should not be used more frequently than recommended (twice daily), at higher doses or with any additional long-acting beta",
"     <sub>",
"      2",
"     </sub>",
"     -adrenergic agonist; adverse cardiovascular effects (possibly fatal) have been reported with excessive beta",
"     <sub>",
"      2",
"     </sub>",
"     -adrenergic overstimulation.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Fatalities have occurred due to adrenal insufficiency in asthmatic patients during and after switching from systemic corticosteroids to inhaled steroids; several months may be required for full recovery of hypothalamic-pituitary-adrenal (HPA) function; patients receiving higher doses of systemic corticosteroids (eg, adults receiving &ge;20 mg of prednisone per day) may be at greater risk; during this period of adrenal suppression, inhaled steroids do not provide the systemic glucocorticoid or mineralocorticoid activity  needed to treat patients requiring stress doses (ie, patients with major stress such as trauma, surgery, infections, or other conditions associated with severe electrolyte loss); when used at high doses  HPA suppression may occur; use of inhaled or systemic corticosteroids (even alternate-day dosing) may increase risk of HPA suppression. Acute adrenal insufficiency may occur with abrupt withdrawal after long-term use or with stress; withdrawal and discontinuation of corticosteroid therapy should be done carefully; patients with HPA axis suppression may require doses of systemic glucocorticosteroids prior to, during, and after unusual stress (eg, surgery). Switching patients from systemic corticosteroids to inhaled steroids may unmask allergic conditions (eg, rhinitis, conjunctivitis, eczema, arthritis, eosinophilic conditions) previously suppressed by the systemic steroid. Immunosuppression may occur; patients may be more susceptible to infections; avoid exposure to chickenpox and measles. Lower respiratory tract infections, including pneumonia, have been reported in patients with COPD using the oral inhalation with an even higher incidence in the elderly.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     <i>",
"      C. albicans",
"     </i>",
"     infections of the mouth and pharynx may occur with orally inhaled corticosteroid use, mostly mild to moderate; interruption of therapy may be necessary at times while antifungal therapy is employed; advise patients to rinse mouth after use. Hypersensitivity reactions with angioedema and swelling of the lips, tongue, and pharynx have been reported rarely.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Not recommended for use with strong CYP3A4 inhibitors (eg, ketoconazole, ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin) due to potential for an increased risk of cardiovascular events and may also increase mometasone serum concentrations and result in systemic corticosteroids effects.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F173447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F173408\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphotericin B: Corticosteroids (Orally Inhaled) may enhance the hypokalemic effect of Amphotericin B.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents: Corticosteroids (Orally Inhaled) may diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May increase the serum concentration of Fluticasone (Oral Inhalation).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of Fluticasone (Oral Inhalation).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of Corticosteroids (Orally Inhaled). Management: Monitor for signs and symptoms of adrenal suppression if inhaled budesonide or mometasone are coadministered with a strong CYP3A4 inhibitor.  Avoid combining inhaled fluticasone with any strong CYP3A4 inhibitor.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Corticosteroids (Orally Inhaled) may enhance the hypokalemic effect of Loop Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Corticosteroids may decrease the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Corticosteroids.  Management: Concurrent use of telaprevir and systemic corticosteroids is not recommended.  When possible, consider alternatives.  If used together, employ extra caution and monitor closely for excessive corticosteroid effects and diminished telaprevir effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Corticosteroids (Orally Inhaled) may enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F173410\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F173424\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1058775\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pulmonary function tests, vital signs, CNS stimulation, serum glucose, serum potassium; check mucous membranes for signs of fungal infection; monitor growth in pediatric patients",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1058766\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Fluticasone: Controls the rate of protein synthesis, depresses the migration of polymorphonuclear leukocytes and fibroblasts, reverses capillary permeability, and stabilizes lysosomal membranes at the cellular level to prevent or control inflammation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Salmeterol: Relaxes bronchial smooth muscle by selective action on beta",
"     <sub>",
"      2",
"     </sub>",
"     -receptors with little effect on heart rate",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1058782\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1058783\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1058774\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?8/16/8454?source=see_link\">",
"      see \"Fluticasone and salmeterol: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not use to treat acute symptoms; do not exceed the prescribed dose of fluticasone/salmeterol; rinse mouth after each use; report sore mouth or mouth lesions to physician; avoid exposure to chickenpox or measles; if exposed, seek medical advice without delay; do not use with spacer",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1058785\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     When fluticasone/salmeterol is initiated in patients previously receiving a short-acting beta agonist, instruct the patient to discontinue regular use of the short-acting beta agonist and to utilize the shorter-acting agent for symptomatic acute episodes only.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      National Asthma Education and Prevention Program (NAEPP), &ldquo;Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma,&rdquo;",
"      <i>",
"       Clinical Practice Guidelines",
"      </i>",
"      , National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 08-4051, prepublication 2007; available at file://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/53/23384/abstract-text/17983880/pubmed\" id=\"17983880\" target=\"_blank\">",
"        17983880",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13321 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-F6FDDAB425-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_53_23384=[""].join("\n");
var outline_f22_53_23384=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708807\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173432\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173433\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058776\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058769\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173414\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173400\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874505\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058780\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058772\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058779\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173461\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173458\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058784\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058768\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058767\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173447\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173408\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173410\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173424\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058775\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058766\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058782\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058783\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058774\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058785\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13321\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13321|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?25/33/26136?source=related_link\">",
"      Fluticasone and salmeterol: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?8/16/8454?source=related_link\">",
"      Fluticasone and salmeterol: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_53_23385="Clinical manifestations and diagnosis of coarctation of the aorta";
var content_f22_53_23385=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and diagnosis of coarctation of the aorta",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/53/23385/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/53/23385/contributors\">",
"     Brojendra N Agarwala, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/53/23385/contributors\">",
"     Emile Bacha, MD, FACS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/53/23385/contributors\">",
"     Qi Ling Cao, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/53/23385/contributors\">",
"     Ziyad M Hijazi, MD, MPH, FAAP, FACC, FSCAI, FAHA",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/53/23385/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/53/23385/contributors\">",
"     David R Fulton, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/53/23385/contributors\">",
"     Heidi M Connolly, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/53/23385/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/53/23385/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/53/23385/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/53/23385/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 21, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coarctation of the aorta is a narrowing of the descending aorta, which is typically located at the insertion of the ductus arteriosus just distal to the left subclavian artery (",
"    <a class=\"graphic graphic_figure graphicRef62095 \" href=\"UTD.htm?40/3/41014\">",
"     figure 1",
"    </a>",
"    ). This defect generally results in left ventricular pressure overload. &nbsp;",
"   </p>",
"   <p>",
"    The clinical manifestations and diagnosis of coarctation of the aorta will be reviewed here. The management of coarctation, including corrective treatment options, and outcome, including the risk of recurrent coarctation, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/27/20922?source=see_link\">",
"     \"Management of coarctation of the aorta\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coarctation of the aorta accounts for 4 to 6 percent of all congenital heart defects with a reported prevalence of about 4 per 10,000 live births [",
"    <a class=\"abstract\" href=\"UTD.htm?22/53/23385/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. It occurs more commonly in males than in females (59 versus 41 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/53/23385/abstract/3\">",
"     3",
"    </a>",
"    ]. Most cases are sporadic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS AND ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there are acquired causes, the etiology of coarctation of the aorta is generally congenital.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Congenital",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vast majority of coarctation cases are congenital. Although the precise pathogenesis is unknown, the two main theories for the development of congenital coarctation of the aorta are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reduced antegrade intrauterine blood flow causing underdevelopment of the fetal aortic arch [",
"      <a class=\"abstract\" href=\"UTD.htm?22/53/23385/abstract/4\">",
"       4",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Migration or extension of ductal tissue into the wall of the fetal thoracic aorta [",
"      <a class=\"abstract\" href=\"UTD.htm?22/53/23385/abstract/5-7\">",
"       5-7",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is also increasing evidence of a vascular wall defect in the ascending aorta of individuals with congenital coarctation of aorta. Pathologic examination of patients with congenital coarctation of the aorta reveals medial thickening and intimal hyperplasia forming a posterolateral ridge that encircles the aortic lumen. In addition, the following are reported aortic wall abnormalities in neonates with coarctation of the aorta [",
"    <a class=\"abstract\" href=\"UTD.htm?22/53/23385/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study that evaluated the elastic properties of the aortic wall, newborns with coarctation of the aorta, both before and after surgical repair, had increased aortic wall stiffness and decreased aortic distensibility compared with neonates without coarctation [",
"      <a class=\"abstract\" href=\"UTD.htm?22/53/23385/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Pathologic analysis from surgical specimens showed increased collagen and decreased smooth muscle mass in the prestenotic compared with poststenotic segments of patients with coarctation [",
"      <a class=\"abstract\" href=\"UTD.htm?22/53/23385/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Histologic examination of surgical or autopsy specimens revealed cystic medial necrosis, defined as depletion and disarray of elastic tissue [",
"      <a class=\"abstract\" href=\"UTD.htm?22/53/23385/abstract/10\">",
"       10",
"      </a>",
"      ]. In some cases, the findings were present at or near birth, suggesting that these changes occurred in utero.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The underlying mechanism for these arterial wall abnormalities is unknown. There may be a role for genetic defects",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    intrauterine insults such as impaired blood flow that alter endothelial development and that result in disturbances in the elastic properties and narrowing of the aorta. The intrinsic defect in the aortic wall appears to predispose to dissection or rupture in the ascending aorta or in the area of the coarctation",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1053215312\">",
"    <span class=\"h3\">",
"     Genetic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A genetic predisposition is suggested by reports of coarctation occurring in family members [",
"    <a class=\"abstract\" href=\"UTD.htm?22/53/23385/abstract/11-13\">",
"     11-13",
"    </a>",
"    ] and by its association with Turner syndrome.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is increasing evidence of an increased familial risk for congenital left ventricular outflow tract obstruction malformations (LVOTO) including coarctation of the aorta [",
"      <a class=\"abstract\" href=\"UTD.htm?22/53/23385/abstract/11,12\">",
"       11,12",
"      </a>",
"      ]. This was shown in a study of family members of 124 patients with LVOTO [",
"      <a class=\"abstract\" href=\"UTD.htm?22/53/23385/abstract/11\">",
"       11",
"      </a>",
"      ]. Thirty of the 351 (9 percent) relatives who were evaluated had asymptomatic LVOTO structural heart defects that included abnormalities in the aortic arch (three), left ventricle (five), and aortic valve (21). Segregation analysis suggests these findings may be the result of one or more minor loci with rare dominant alleles.",
"     </li>",
"     <li>",
"      In patients with Turner syndrome (females with a loss of an X chromosome), the reported incidence of coarctation of the aorta is between 3 and 10 percent. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33449?source=see_link&amp;anchor=H9#H9\">",
"       \"Clinical manifestations and diagnosis of Turner syndrome (gonadal dysgenesis)\", section on 'Cardiovascular disease'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Acquired",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to a congenital etiology, aortic narrowing can be an acquired abnormality due to inflammatory diseases of the aorta, such as Takayasu arteritis or, rarely, severe atherosclerosis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/53/23385/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. In the former disorder, the midthoracic or abdominal aorta is often the site of involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?22/53/23385/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/19/13624?source=see_link\">",
"     \"Clinical features and diagnosis of Takayasu arteritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1053215422\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1053215635\">",
"    <span class=\"h2\">",
"     Anatomical variants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although most patients have a discrete narrowing of the descending aorta at the insertion of the ductus arteriosus, there is a spectrum of aortic narrowing that encompasses the usual discrete thoracic lesions, long-segmental defects, tubular hypoplasia, and, rarely, coarctation located in the abdominal aorta.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1053215674\">",
"    <span class=\"h2\">",
"     Other cardiac lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coarctation of the aorta is usually accompanied by another cardiac lesion [",
"    <a class=\"abstract\" href=\"UTD.htm?22/53/23385/abstract/17-19\">",
"     17-19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a large case series of 1892 patients from Boston Children&rsquo;s Hospital, only 7 percent of cases did not have any other cardiac anomaly other than bicuspid aortic valve [",
"      <a class=\"abstract\" href=\"UTD.htm?22/53/23385/abstract/18\">",
"       18",
"      </a>",
"      ]. About one-third of patients had other complex cardiac defects (including single ventricle variants, atrioventricular [AV] canal defect or D-transposition of the great arteries [TGA]), 18 percent had a ventricular septal defect (VSD). In the remaining 806 patients (42 percent) who were classified as uncomplicated coarctation, other cardiac anomalies included bicuspid aortic valve (50 percent), atrial septal defect or patent ductus arteriosus (PDA, 38 percent), mitral regurgitation (35 percent), aortic stenosis (29 percent), aortic regurgitation (28 percent), and mitral stenosis (16 percent), and, in only 17 percent of uncomplicated cases, no other lesions were detected.",
"     </li>",
"     <li>",
"      In a second case series of 216 infants (less than one year of age) from Michigan, 48 percent of patients were diagnosed with complex coarctation due to the presence of other cardiac defects including VSD, aortic and subaortic stenosis, AV canal defect, and d-TGA [",
"      <a class=\"abstract\" href=\"UTD.htm?22/53/23385/abstract/19\">",
"       19",
"      </a>",
"      ]. The remaining 113 patients were diagnosed with simple coarctation; however, PDA occurred in 48 patients (42 percent). As a result, about one-third of affected infants did not have another detected cardiac anomaly. In this series, it is unclear whether an evaluation to detect the presence of bicuspid aortic valve was performed.",
"     </li>",
"     <li>",
"      In a third case series of 500 patients, who were primarily adult patients referred for magnetic resonance imaging, 17 percent had no additional cardiovascular anomalies [",
"      <a class=\"abstract\" href=\"UTD.htm?22/53/23385/abstract/17\">",
"       17",
"      </a>",
"      ]. In this cohort, bicuspid aortic valves, arch hypoplasia, VSD, and PDA were detected in 60, 14, 13, and 7 percent of patients, respectively",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1053215802\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coarctation of the aorta does not cause a hemodynamic problem in utero two-third of the combined cardiac output flows through the patent ductus arteriosus (PDA) into the descending thoracic aorta, bypassing the site of constriction at the isthmus (",
"    <a class=\"graphic graphic_figure graphicRef66765 \" href=\"UTD.htm?14/43/15032\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    During the neonatal period, when the PDA and foramen ovale (between the right and left atria) begin to close, the cardiac output that must cross the narrowed aortic segment to reach the lower extremities steadily increases. With these changes, the hemodynamic changes may range from mild systolic hypertension to severe heart failure depending upon the severity of the coarctation and upon the presence of other associated lesions.",
"   </p>",
"   <p>",
"    At birth, the left ventricular afterload increases because of outflow tract obstruction resulting in increased systolic pressure in the left ventricle and proximal aorta. In cases of severe obstruction, the systolic pressure gradient may reach 50 to 60 mmHg at rest.",
"   </p>",
"   <p>",
"    Several compensatory mechanisms arise to surmount the left ventricular outflow tract obstruction. These include left ventricular myocardial hypertrophy, which maintains normal systolic function and ejection fraction, and the development of collateral blood flow involving the intercostal, internal mammary, and scapular vessels, which circumvents the stenotic lesion [",
"    <a class=\"abstract\" href=\"UTD.htm?22/53/23385/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. However, in neonates with severe lesions, heart failure may develop because there is insufficient time for the development of myocardial hypertrophy or collateral blood flow.",
"   </p>",
"   <p>",
"    Other cardiac lesions may add further strain on ventricular function. Valvar and subvalvar aortic stenosis may further increase left ventricular systolic pressure and afterload, whereas a large ventricular septal defect, patent ductus arteriosus, or mitral regurgitation will increase left ventricular end-diastolic volume and preload, which subsequently leads to increased left ventricular end-diastolic pressure and to pulmonary artery hypertension. These patients with complex coarctation are likely to develop heart failure and pulmonary artery hypertension.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Manifestations according to age",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of coarctation vary in different age groups. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/52/35656?source=see_link\">",
"     \"Clinical manifestations and diagnosis of patent ductus arteriosus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Neonates",
"    </span>",
"    &nbsp;&mdash;&nbsp;The newborn infant may remain asymptomatic if there is a persistent patent ductus arteriosus (PDA) or if the coarctation is not severe. On physical examination, a clinical diagnosis is made if there is an absent or delayed femoral pulse (when compared with the brachial pulse). A murmur may be associated with other cardiac defects, such as PDA, aortic stenosis, or ventricular septal defect (VSD). A systolic click may be heard due to a bicuspid aortic valve. Differential cyanosis is seen in a neonate with severe coarctation of the aorta and with a large PDA with a right-to-left shunt into the descending thoracic aorta.",
"   </p>",
"   <p>",
"    A neonate with severe coarctation may present with heart failure",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    shock when the PDA closes. These patients are pale, irritable, diaphoretic, and dyspneic with absent femoral pulses and, often, hepatomegaly. The pulses may be poor in all four extremities. In the clinical setting of neonatal shock, important diagnoses to consider include severe coarctation, sepsis, and metabolic abnormalities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/27/20922?source=see_link&amp;anchor=H3#H3\">",
"     \"Management of coarctation of the aorta\", section on 'Critical coarctation in infancy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/15/9466?source=see_link&amp;anchor=H23884780#H23884780\">",
"     \"Etiology and diagnosis of heart failure in infants and children\", section on 'Clinical manifestations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24489?source=see_link\">",
"     \"Inborn errors of metabolism: Epidemiology, pathogenesis, and clinical features\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/0/10250?source=see_link\">",
"     \"Inborn errors of metabolism: Metabolic emergencies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Older infants and children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnosis is often delayed in older infants and children because physical findings are subtle and because most patients are asymptomatic. With careful history taking, some patients will report chest pain, cold extremities, and claudication with physical exertion. However, these are often noted after the diagnosis of coarctation is made.",
"   </p>",
"   <p>",
"    Careful measurement of blood pressure and palpation of pulses in all four extremities suggest the clinical diagnosis with differential pressures between the upper and lower extremities or pulse delay in the lower extremities. In young children, coarctation of the aorta may present with hypertension",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    murmurs resulting from collaterals or associated heart defects. Heart failure rarely occurs beyond the neonatal period.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;In previously undiagnosed adults, the classic presenting sign is hypertension. Despite the variability in blood pressure in the upper and lower extremities, regional blood flow is generally maintained within normal limits by autoregulatory vasoconstriction in the hypertensive areas and by vasodilation in the hypotensive areas [",
"    <a class=\"abstract\" href=\"UTD.htm?22/53/23385/abstract/20\">",
"     20",
"    </a>",
"    ]. Most patients are asymptomatic unless severe hypertension is present, which may lead to headache, epistaxis, heart failure, or aortic dissection. In addition, claudication of the lower extremities can occur due to reduced flow, especially with physical exertion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1088179575\">",
"    <span class=\"h2\">",
"     Natural history",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data on the natural history of coarctation of the aorta are largely derived from hospital postmortem records and from case series prior to the availability of operative repair (introduced in 1945) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/53/23385/abstract/21\">",
"     21",
"    </a>",
"    ]. The average survival age of individuals with unoperated coarctation was approximately 35 years of age, with 75 percent mortality by 46 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?22/53/23385/abstract/22\">",
"     22",
"    </a>",
"    ]. Common complications in unoperated patients or in those operated on during later childhood or adulthood were systemic hypertension, accelerated coronary artery disease, stroke, aortic dissection, and heart failure. Causes of death include heart failure, aortic rupture, aortic dissection, endocarditis, endarteritis, intracerebral hemorrhage, and myocardial infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?22/53/23385/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Patients with an associated bicuspid aortic valve may also develop significant aortic stenosis or aortic regurgitation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/1/6169?source=see_link\">",
"     \"Clinical manifestations and diagnosis of bicuspid aortic valve\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1088179206\">",
"    <span class=\"h2\">",
"     Physical findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;The findings of differential systolic blood pressures between the upper and lower extremities or pulse delay in the lower extremities suggest a diagnosis of coarctation of the aorta, which is usually confirmed by echocardiography or alternate imaging modalities. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1088178828\">",
"    <span class=\"h3\">",
"     Blood pressure and pulses",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classic findings of coarctation of the aorta are systolic hypertension in the upper extremities, diminished or delayed femoral pulses (brachial-femoral delay), and low or unobtainable arterial blood pressure in the lower extremities (",
"    <a class=\"graphic graphic_figure graphicRef72344 \" href=\"UTD.htm?43/36/44622\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/53/23385/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/21/27991?source=see_link\">",
"     \"Who should be evaluated for renovascular or other causes of secondary hypertension?\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/45/17113?source=see_link&amp;anchor=H13#H13\">",
"     \"Definition and diagnosis of hypertension in children and adolescents\", section on 'Technique of BP measurement'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In our practice, we follow the recommendations outlined by the 2008 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association guidelines for adults with congenital heart disease to screen for coarctation in both hypertensive children and adults [",
"    <a class=\"abstract\" href=\"UTD.htm?22/53/23385/abstract/22\">",
"     22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Every patient with systemic arterial hypertension should have the brachial and femoral pulses palpated simultaneously to assess timing and amplitude to search for the &ldquo;brachial-femoral delay&rdquo; of significant aortic coarctation (",
"      <a class=\"graphic graphic_figure graphicRef72344 \" href=\"UTD.htm?43/36/44622\">",
"       figure 3",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/15/33013?source=see_link&amp;anchor=H2#H2\">",
"       \"Examination of the arterial pulse\", section on 'Unequal or delayed pulses'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Supine bilateral arm (brachial artery) blood pressures and prone right or left supine leg (popliteal) blood pressures should be measured to search for differential pressure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The site of origin of the left subclavian artery and the severity of the coarctation determine the pattern of pulse and blood pressure findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In most cases, the origin of the left subclavian artery is proximal to the coarctation, resulting in hypertension in both arms (",
"      <a class=\"graphic graphic_figure graphicRef62095 \" href=\"UTD.htm?40/3/41014\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Less often, the origin of the left subclavian artery is just distal to the coarctation, so the left brachial pulse is diminished and is equal to the femoral pulse.",
"     </li>",
"     <li>",
"      In approximately 3 to 4 percent of cases, both the right and left subclavian arteries originate below the area of coarctation, resulting in the blood pressures and pulses that are equally decreased in all four extremities.",
"     </li>",
"     <li>",
"      In mild coarctation of the aorta, all the pulses may be easily palpable, but there may be a delay in the femoral pulse compared with the brachial pulse.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The mechanical obstruction to flow is largely responsible for the elevation of blood pressure in the upper extremities. In addition, renal hypoperfusion may lead to enhanced renin secretion and to subsequent volume expansion [",
"    <a class=\"abstract\" href=\"UTD.htm?22/53/23385/abstract/24\">",
"     24",
"    </a>",
"    ]. Volume expansion produces a further elevation in blood pressure, restoring renal perfusion and renin secretion toward normal.",
"   </p>",
"   <p>",
"    Because other conditions can also cause unequal pulses and blood pressures (eg, atherosclerotic disease, aortic dissection), these disorders should also be considered when pulse and blood pressure discrepancies are found. (See",
"    <a class=\"local\" href=\"#H1088180658\">",
"     'Differential diagnosis'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/15/33013?source=see_link&amp;anchor=H2#H2\">",
"     \"Examination of the arterial pulse\", section on 'Unequal or delayed pulses'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When coarctation of the aorta is accompanied by substantial collaterals, the femoral pulses may be less diminished, and the gradient (differential systolic blood pressures) across the coarctation may be less severe than expected for the degree of obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?22/53/23385/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Cardiac examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac auscultation is usually normal if there are no associated cardiac abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?22/53/23385/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The first and second heart sounds are usually normal. Rarely, pulmonary hypertension is present; when this occurs, the pulmonic component of the second heart sound is accentuated.",
"     </li>",
"     <li>",
"      There may be an ejection systolic click and a systolic ejection murmur from a bicuspid aortic valve, which is heard best at the apex or left sternal border. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/56/22410?source=see_link&amp;anchor=H33#H33\">",
"       \"Auscultation of heart sounds\", section on 'Ejection sounds'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26202?source=see_link&amp;anchor=H11#H11\">",
"       \"Auscultation of cardiac murmurs\", section on 'Midsystolic ejection murmurs'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A systolic murmur can extend beyond the second heart sound, at the left paravertebral interscapular area, due to flow across the narrow coarctation area.",
"     </li>",
"     <li>",
"      Continuous murmurs may be caused by flow through large collateral vessels. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26202?source=see_link&amp;anchor=H52#H52\">",
"       \"Auscultation of cardiac murmurs\", section on 'Continuous murmurs'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Systolic murmurs may be present due to coexisting cardiac defects (PDA, VSD, or aortic stenosis)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In infants with heart failure, a prominent right ventricular impulse is typical. In older children and adults, the left ventricular impulse is palpable and sustained, and pulsations may be palpable in the intercostal spaces from large collateral arteries. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/43/9909?source=see_link\">",
"     \"Examination of the precordial pulsation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1088179382\">",
"    <span class=\"h2\">",
"     Tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients will undergo initial testing that includes electrocardiography (ECG) and chest radiography. However, the diagnosis is generally confirmed by echocardiography or by magnetic resonance imaging.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1088179443\">",
"    <span class=\"h3\">",
"     Electrocardiogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;ECG varies with age of the patient and severity of the lesion. Even in neonates and young infants with a severe defect, the ECG may be normal and may display the age-appropriate right ventricular hypertrophy. In older children and adults, the ECG either may be normal or may show left ventricular hypertrophy, with increased voltage and ST and T wave changes in the left precordial leads. The ECG will occasionally show right ventricular conduction delay [",
"    <a class=\"abstract\" href=\"UTD.htm?22/53/23385/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/13/3285?source=see_link\">",
"     \"Electrocardiographic diagnosis of left ventricular hypertrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1088179450\">",
"    <span class=\"h3\">",
"     Chest radiograph",
"    </span>",
"    &nbsp;&mdash;&nbsp;The chest radiograph varies with age and severity of the coarctation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In infants with heart failure, the chest radiograph shows generalized cardiomegaly with increased pulmonary vascular markings due to pulmonary venous congestion (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef88511 \" href=\"UTD.htm?31/50/32544\">",
"       image 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      In older children and adults, the heart size may be normal, but the following abnormalities are often present:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Notching of the posterior one-third of the third to eighth ribs due to erosion by the large collateral arteries. Rib notching increases with age and usually becomes apparent between the ages of 4 and 12 years (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef87707 \" href=\"UTD.htm?18/19/18738\">",
"       image 2",
"      </a>",
"      ). Notching is not seen in the anterior ribs because the anterior intercostal arteries are not located in costal grooves [",
"      <a class=\"abstract\" href=\"UTD.htm?22/53/23385/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Indentation of the aortic wall at the site of coarctation with pre- and post-coarctation dilatation, which can produce a &ldquo;3&rdquo; sign (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef87857 \" href=\"UTD.htm?25/63/26609\">",
"       image 3",
"      </a>",
"      ) .",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"       Barium",
"      </a>",
"      swallow and cardiac angiogram, which are no longer performed routinely, may show a reverse &ldquo;3&rdquo; or &ldquo;E&rdquo; sign (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef87858 \" href=\"UTD.htm?33/34/34336\">",
"       image 4",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1088180758\">",
"    <span class=\"h2\">",
"     Noncardiac manifestations",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Intracranial hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with coarctation of the aorta are at risk for intracranial aneurysms [",
"    <a class=\"abstract\" href=\"UTD.htm?22/53/23385/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. This was best illustrated by a study of 100 patients with coarctation that demonstrated 10 patients had an intracranial aneurysm detected by brain magnetic resonance angiography [",
"    <a class=\"abstract\" href=\"UTD.htm?22/53/23385/abstract/27\">",
"     27",
"    </a>",
"    ]. This incidence is higher than the reported rate of intracranial aneurysms in the general population (10 versus 2 percent).",
"   </p>",
"   <p>",
"    In addition, subarachnoid or intracerebral hemorrhage has been reported in patients with coarctation. These have primarily occurred in patients between 10 and 30 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?22/53/23385/abstract/26\">",
"     26",
"    </a>",
"    ], but cerebral hemorrhage also has been reported in neonates [",
"    <a class=\"abstract\" href=\"UTD.htm?22/53/23385/abstract/28\">",
"     28",
"    </a>",
"    ]. Hypertension is not a necessary precondition as cerebral hemorrhage can occur in normotensive or mildly hypertensive patients long after successful coarctation repair [",
"    <a class=\"abstract\" href=\"UTD.htm?22/53/23385/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to the risk of intracranial aneurysms, dilated collateral arteries within the spinal canal may accompany coarctation. These vessels can compress the spinal cord or can rupture, causing a clinical picture of subarachnoid hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?22/53/23385/abstract/30-32\">",
"     30-32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Turner syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because patients with Turner syndrome have about a 10 percent risk of coarctation, all phenotypic female patients should be examined for the dysmorphic features of Turner syndrome:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neonates may have congenital lymphedema of the hands and feet, a webbed neck, and a low hairline",
"     </li>",
"     <li>",
"      Older girls and women are typically short with a broad, shield-shaped chest and with widely spaced nipples.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Women with Turner syndrome are generally infertile; however, pregnancy can be achieved through oocyte donation. Cardiac evaluation should be performed before initiating fertility therapy because these patients are at increased risk of death from rupture or dissection of the aorta during pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33449?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical manifestations and diagnosis of Turner syndrome (gonadal dysgenesis)\", section on 'Clinical manifestations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/63/14329?source=see_link&amp;anchor=H20#H20\">",
"     \"Management of Turner syndrome (gonadal dysgenesis)\", section on 'Fertility'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Prenatal diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prenatal diagnosis is difficult as it is challenging to detect the coarctation by antenatal ultrasound because only 10 percent of the fetal cardiac output flows across the defect (",
"    <a class=\"graphic graphic_figure graphicRef66765 \" href=\"UTD.htm?14/43/15032\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/53/23385/abstract/33-35\">",
"     33-35",
"    </a>",
"    ]. In addition, the presence of the patent ductus limits the ability to detect any pressure gradient at the coarctation site, and may also make the anatomic narrowing less marked. If the diagnosis is made, it can be made as early as 16 to 18 weeks of gestational age. The presence of a long segment coarctation or other cardiac findings (eg small left ventricle, small mitral annulus, or dilated right ventricle) improves detection.",
"   </p>",
"   <p>",
"    Antenatal detection by echocardiography appears to be improved by serial studies that use transverse views of the aortic and ductal arches, which compare the ratio of the aortic and ductal arches with normative data [",
"    <a class=\"abstract\" href=\"UTD.htm?22/53/23385/abstract/36\">",
"     36",
"    </a>",
"    ]. Fetuses with coarctation compared with those without coarctation were more likely to have a lower ratio of the distal aortic isthmus to arterial duct diameters.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1088180874\">",
"    <span class=\"h2\">",
"     Postnatal diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical diagnosis of coarctation of the aorta is based upon the characteristic findings of systolic hypertension in the upper extremities, diminished or delayed femoral pulses (brachial-femoral delay), and low or unobtainable arterial blood pressure in the lower extremities. The diagnosis is confirmed by noninvasive imaging methods, particularly echocardiography.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most patients, high-quality two-dimensional and Doppler echocardiography can establish the diagnosis and severity of coarctation of the aorta including in neonates with a patent ductus arteriosus [",
"    <a class=\"abstract\" href=\"UTD.htm?22/53/23385/abstract/22,37-39\">",
"     22,37-39",
"    </a>",
"    ]. Echocardiography can also detect associated cardiac defects and aortic hypoplasia and can be used for follow-up after repair [",
"    <a class=\"abstract\" href=\"UTD.htm?22/53/23385/abstract/37,38\">",
"     37,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the high parasternal or suprasternal long axis view, a discrete area of narrowing (posterior shelf) within the lumen of the proximal descending thoracic aorta is typically visualized (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef58827 \" href=\"UTD.htm?25/8/25730\">",
"     image 5",
"    </a>",
"    ). Color and pulsed Doppler echocardiography can localize the area of coarctation by demonstrating increased velocities and turbulence, as well as forward diastolic flow.",
"   </p>",
"   <p>",
"    Continuous wave Doppler can estimate the severity of coarctation based upon the maximal flow velocity across the narrow area, by calculating the pressure gradient across the coarctation with appropriate correction for velocity prior to the site of coarctation. The severity of coarctation can also be estimated by calculating the ratio of the maximal velocity across the coarctation (in the suprasternal view) to the peak velocity in the abdominal aorta (in the subcostal view) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/53/23385/abstract/37\">",
"     37",
"    </a>",
"    ]. Of note, the presence of collateral blood flow may diminish the gradient across the coarctation measured by Doppler and may be less severe than expected for the degree of obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?22/53/23385/abstract/22\">",
"     22",
"    </a>",
"    ]. Therefore, indications for intervention are not based solely upon gradient size. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/27/20922?source=see_link\">",
"     \"Management of coarctation of the aorta\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Identification of characteristic diastolic run-off should be included in the routine evaluation for coarctation because low amplitude, undulating, continuous Doppler flow within the descending thoracic aorta below the area of coarctation and within the abdominal aorta provides indirect evidence of coarctation. Abnormal flow in collateral vessels may also be detected by color flow and pulse Doppler. Pulsed-wave Doppler assessment of the abdominal aorta in patients with coarctation generally demonstrates reduced and delayed systolic amplitude with persistent flow during diastole. This finding may be the first clue to the echocardiographic diagnosis of coarctation.",
"   </p>",
"   <p>",
"    Because most patients with coarctation will also have other cardiac anomalies, echocardiographic evaluation should also include measurement of the dimensions of the aortic annulus, aortic sinuses, sinotubular ridge, and ascending aorta; identification of aortic valve anatomy; determination of left ventricular size and function; and identification of any potential associated lesions such as ventricular septal defect, subvalvular aortic stenosis, and mitral valve deformity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Magnetic resonance imaging/computed tomography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance (MR) or computed tomography (CT) angiography clearly defines the location and severity of coarctation of the aorta, as well as collateral vessels [",
"    <a class=\"abstract\" href=\"UTD.htm?22/53/23385/abstract/37\">",
"     37",
"    </a>",
"    ]. MR imaging (MRI) also may accurately identify patients with significant pressure gradient across the coarctation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/53/23385/abstract/40,41\">",
"     40,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In children with coarctation, echocardiography often is adequate for the surgeon or interventional cardiologist without the need for a further imaging study. However, echocardiography may be insufficient to confirm the diagnosis, especially in adolescent and adult patients. In the 2008 American College of Cardiology and American Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    adult congenital heart disease guidelines, it is recommended that every adult patient with coarctation (repaired or not) should have at least one cardiovascular MRI or computed tomography for complete evaluation of the thoracic aorta [",
"    <a class=\"abstract\" href=\"UTD.htm?22/53/23385/abstract/22\">",
"     22",
"    </a>",
"    ]. MR imaging can also detect associated cardiac abnormalities and can be used for serial follow-up after surgical repair or balloon angioplasty [",
"    <a class=\"abstract\" href=\"UTD.htm?22/53/23385/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cranial MR angiography is also appropriate to search for intracranial aneurysms.",
"   </p>",
"   <p>",
"    If MRI is contraindicated, CT imaging may be used to diagnose coarctation. MRI is preferred to CT because of the high amount of radiation associated with CT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Cardiac catheterization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the accuracy of noninvasive methods for diagnosis and determination of severity [",
"    <a class=\"abstract\" href=\"UTD.htm?22/53/23385/abstract/42\">",
"     42",
"    </a>",
"    ], cardiac catheterization for an isolated coarctation of the aorta in children is generally a therapeutic intervention (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef79548 \" href=\"UTD.htm?41/33/42527\">",
"     image 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/53/23385/abstract/42\">",
"     42",
"    </a>",
"    ]. Catheterization may also be necessary when coarctation is associated with complex cardiac defects.",
"   </p>",
"   <p>",
"    In adults, cardiac catheterization is indicated when associated coronary artery disease is suspected and surgery is planned or is indicated if catheter-based intervention is to be performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1088180658\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis for coarctation varies based upon the clinical presentation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the clinical setting of neonatal heart failure, the differential diagnosis of severe coarctation resulting in heart failure includes other cardiac diseases that result in severe left obstructed heart flow or failure (eg, hypoplastic left heart syndrome and severe critical aortic valve stenosis), sepsis, myocarditis, and perinatal hypoxia. Echocardiography distinguishes these disorders from coarctation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/2/39975?source=see_link&amp;anchor=H3#H3\">",
"       \"Etiology, clinical manifestations, and evaluation of neonatal shock\", section on 'Etiology'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients with unequal pulses and blood pressures, the differential diagnosis includes obstructive peripheral arterial diseases (eg, from atherosclerosis, or arterial thrombosis from prior catheterization), prior surgical ligation (eg, history of classic Blalock Taussig shunt), aortic dissection and aneurysm, and supravalvar aortic stenosis. Echocardiography distinguishes coarctation from these disorders.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics links (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?40/43/41649?source=see_link\">",
"       \"Patient information: Aortic coarctation in adults (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/47/25329?source=see_link\">",
"       \"Patient information: Aortic coarctation in children (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Coarctation of the aorta is a common malformation accounting for 4 to 6 percent of all congenital heart defects with a prevalence of 4 per 100,000 live births. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although there are acquired causes, the etiology of coarctation of the aorta is generally congenital. The underlying pathogenesis is unknown. There may be a genetic predisposition based upon familial risk of left ventricular outflow tract obstructive malformations including coarctation and upon the association of Turner syndrome and coarctation. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathogenesis and etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is a spectrum of anatomic variants from the usual discrete thoracic lesions to long-segmental defects, tubular hypoplasia, and, rarely, coarctation of the abdominal aorta. Coarctation of the aorta is usually accompanied by another cardiac lesion including bicuspid aortic valve, ventricular septal defect, and patent ductus arteriosus (PDA). (See",
"      <a class=\"local\" href=\"#H1053215422\">",
"       'Anatomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The postnatal presentation varies depending upon the age of the patient and the severity of the lesion. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Manifestations according to age'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Neonates may be asymptomatic if there is a persistent PDA or if the coarctation is not severe. However, patients with severe defects may present with heart failure",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      shock when the PDA closes.",
"     </li>",
"     <li>",
"      Older infants and children are often asymptomatic and present with hypertension, with murmurs caused by collateral blood flow or associated heart defects, or with complaints of chest pain or claudication, especially with exertion.",
"     </li>",
"     <li>",
"      In undiagnosed adults, hypertension is the typical presenting sign.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The classical physical findings are differential systolic blood pressure between the upper and lower extremities",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      delayed femoral pulses. The cardiac auscultation is usually normal if there is no associated cardiac abnormality. (See",
"      <a class=\"local\" href=\"#H1088179206\">",
"       'Physical findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that every individual with systemic arterial hypertension should be assessed for the presence of a coarctation by simultaneous palpation of the brachial and femoral pulses to detect the presence of a &ldquo;brachial-femoral delay&rdquo; and by supine bilateral arm blood pressures and prone right or left supine leg blood pressures to detect any differential pressure (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1088178828\">",
"       'Blood pressure and pulses'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/15/33013?source=see_link&amp;anchor=H2#H2\">",
"       \"Examination of the arterial pulse\", section on 'Unequal or delayed pulses'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Electrocardiogram (ECG) may be normal in the neonate, infant, or adult with coarctation of the aorta. In the neonate with severe disease, right ventricular hypertrophy can be seen. In older children and adults, left ventricular hypertrophy may be present with increased voltage and ST and T wave changes over the left precordial leads. (See",
"      <a class=\"local\" href=\"#H1088179443\">",
"       'Electrocardiogram'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chest radiographic findings vary with age and severity of the coarctation. In infants with heart failure, the chest radiograph usually shows generalized cardiomegaly with increased pulmonary vascular markings due to pulmonary venous congestion (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef88511 \" href=\"UTD.htm?31/50/32544\">",
"       image 1",
"      </a>",
"      ). In older children and adults, the heart size may remain normal, but other findings include rib notching and the &ldquo;3&rdquo; sign (indentation of the aortic wall at the site of coarctation with pre- and post-coarctation dilatation) (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef87707 \" href=\"UTD.htm?18/19/18738\">",
"       image 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef87857 \" href=\"UTD.htm?25/63/26609\">",
"       image 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1088179450\">",
"       'Chest radiograph'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The prenatal diagnosis of coarctation is challenging as it is difficult to detect the narrowing because only 10 percent of the fetal cardiac output flows through the thoracic aorta. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Prenatal diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of coarctation is generally confirmed by two-dimensional and Doppler transthoracic echocardiography. In some cases, further imaging with magnetic resonance imaging (MRI) or computerized tomography (CT) is needed to confirm the diagnosis, to define the location of the obstruction, and to identify collateral vessels. Echocardiography or MRI is also useful for post-repair follow-up. (See",
"      <a class=\"local\" href=\"#H1088180874\">",
"       'Postnatal diagnosis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/27/20922?source=see_link&amp;anchor=H76537727#H76537727\">",
"       \"Management of coarctation of the aorta\", section on 'Monitoring'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Although the differential diagnosis for coarctation varies, these other conditions are usually differentiated from coarctation by echocardiography.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The differential for neonatal heart failure includes sepsis, other cardiac diseases that cause left ventricular outflow tract obstruction, and perinatal hypoxia.",
"     </li>",
"     <li>",
"      The differential for older infants, children, and adults with unequal pulses and blood pressure between upper and lower extremities includes obstructive arterial diseases (eg, atherosclerosis), aortic dissection and aneurysm, and supravalvular aortic stenosis.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23385/abstract/1\">",
"      Reller MD, Strickland MJ, Riehle-Colarusso T, et al. Prevalence of congenital heart defects in metropolitan Atlanta, 1998-2005. J Pediatr 2008; 153:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23385/abstract/2\">",
"      Hoffman JI, Kaplan S. The incidence of congenital heart disease. J Am Coll Cardiol 2002; 39:1890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23385/abstract/3\">",
"      Report of the New England Regional Infant Cardiac Program. Pediatrics 1980; 65:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23385/abstract/4\">",
"      Rudolph AM, Heymann MA, Spitznas U. Hemodynamic considerations in the development of narrowing of the aorta. Am J Cardiol 1972; 30:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23385/abstract/5\">",
"      Wielenga G, Dankmeijer J. Coarctation of the aorta. J Pathol Bacteriol 1968; 95:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23385/abstract/6\">",
"      Russell GA, Berry PJ, Watterson K, et al. Patterns of ductal tissue in coarctation of the aorta in the first three months of life. J Thorac Cardiovasc Surg 1991; 102:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23385/abstract/7\">",
"      Ho SY, Anderson RH. Coarctation, tubular hypoplasia, and the ductus arteriosus. Histological study of 35 specimens. Br Heart J 1979; 41:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23385/abstract/8\">",
"      Vogt M, K&uuml;hn A, Baumgartner D, et al. Impaired elastic properties of the ascending aorta in newborns before and early after successful coarctation repair: proof of a systemic vascular disease of the prestenotic arteries? Circulation 2005; 111:3269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23385/abstract/9\">",
"      Niwa K, Perloff JK, Bhuta SM, et al. Structural abnormalities of great arterial walls in congenital heart disease: light and electron microscopic analyses. Circulation 2001; 103:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23385/abstract/10\">",
"      Isner JM, Donaldson RF, Fulton D, et al. Cystic medial necrosis in coarctation of the aorta: a potential factor contributing to adverse consequences observed after percutaneous balloon angioplasty of coarctation sites. Circulation 1987; 75:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23385/abstract/11\">",
"      McBride KL, Pignatelli R, Lewin M, et al. Inheritance analysis of congenital left ventricular outflow tract obstruction malformations: Segregation, multiplex relative risk, and heritability. Am J Med Genet A 2005; 134A:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23385/abstract/12\">",
"      Wessels MW, Berger RM, Frohn-Mulder IM, et al. Autosomal dominant inheritance of left ventricular outflow tract obstruction. Am J Med Genet A 2005; 134A:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23385/abstract/13\">",
"      Sehested J. Coarctation of the aorta in monozygotic twins. Br Heart J 1982; 47:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23385/abstract/14\">",
"      D'Souza SJ, Tsai WS, Silver MM, et al. Diagnosis and management of stenotic aorto-arteriopathy in childhood. J Pediatr 1998; 132:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23385/abstract/15\">",
"      Pagni S, Denatale RW, Boltax RS. Takayasu's arteritis: the middle aortic syndrome. Am Surg 1996; 62:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23385/abstract/16\">",
"      Sheikhzadeh A, Giannitsis E, Gehl HB, et al. Acquired thromboatheromatous coarctation of the aorta: acquired coarctation of the aorta. Int J Cardiol 1999; 69:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23385/abstract/17\">",
"      Teo LL, Cannell T, Babu-Narayan SV, et al. Prevalence of associated cardiovascular abnormalities in 500 patients with aortic coarctation referred for cardiovascular magnetic resonance imaging to a tertiary center. Pediatr Cardiol 2011; 32:1120.",
"     </a>",
"    </li>",
"    <li>",
"     Keane JF and Flyer DC. Coarctation of the aorta. In: Nadas' Pediatric Cardiology, 2nd Ed., Keane JF, Lock JE, and Fyler DC.  (Eds), Saunders Elsevier, Philadelphia 2006. p.627.",
"    </li>",
"    <li>",
"     Beekman RH III. Coarctation of the Aorta. In: Moss and Adams' Heart Disease in Infants, Children, and Adolescents, 6th Ed., Allen HD, Driscoll DJ, Shaddy RE, Feltes TF.  (Eds), WK Lippincott Willams and Wilkins, Philadelphia 2008. Vol 2, p.987.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23385/abstract/20\">",
"      Tobian L Jr. A viewpoint concerning the enigma of hypertension. Am J Med 1972; 52:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23385/abstract/21\">",
"      Jenkins NP, Ward C. Coarctation of the aorta: natural history and outcome after surgical treatment. QJM 1999; 92:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23385/abstract/22\">",
"      Warnes CA, Williams RG, Bashore TM, et al. ACC/AHA 2008 Guidelines for the Management of Adults with Congenital Heart Disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to develop guidelines on the management of adults with congenital heart disease). Circulation 2008; 118:e714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23385/abstract/23\">",
"      Brickner ME, Hillis LD, Lange RA. Congenital heart disease in adults. First of two parts. N Engl J Med 2000; 342:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23385/abstract/24\">",
"      Alpert BS, Bain HH, Balfe JW, et al. Role of the renin-angiotensin-aldosterone system in hypertensive children with coarctation of the aorta. Am J Cardiol 1979; 43:828.",
"     </a>",
"    </li>",
"    <li>",
"     Perloff JK. Clinical Recognition of Congenital Heart Disease, WB Saunders, Philadelphia 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23385/abstract/26\">",
"      HODES HL, STEINFELD L, BLUMENTHAL S. Congenital cerebral aneurysms and coarctation of the aorta. Arch Pediatr 1959; 76:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23385/abstract/27\">",
"      Connolly HM, Huston J 3rd, Brown RD Jr, et al. Intracranial aneurysms in patients with coarctation of the aorta: a prospective magnetic resonance angiographic study of 100 patients. Mayo Clin Proc 2003; 78:1491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23385/abstract/28\">",
"      Young RS, Liberthson RR, Zalneraitis EL. Cerebral hemorrhage in neonates with coarctation of the aorta. Stroke 1982; 13:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23385/abstract/29\">",
"      Simon AB, Zloto AE. Coarctation of the aorta. Longitudinal assessment of operated patients. Circulation 1974; 50:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23385/abstract/30\">",
"      Banna MM, Rose PG, Pearce GW. Coarctation of the aorta as a cause of spinal subarachnoid hemorrhage. Case report. J Neurosurg 1973; 39:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23385/abstract/31\">",
"      Watson AB. Spinal subarachnoid haemorrhage in patient with coarctation of aorta. Br Med J 1967; 4:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23385/abstract/32\">",
"      Chadduck WM, Cathey SL, Gearhart AT, et al. Paraplegia caused by coarctation of the aorta and hydrocephalus. Childs Nerv Syst 1986; 2:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23385/abstract/33\">",
"      Head CE, Jowett VC, Sharland GK, Simpson JM. Timing of presentation and postnatal outcome of infants suspected of having coarctation of the aorta during fetal life. Heart 2005; 91:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23385/abstract/34\">",
"      Wren C, Reinhardt Z, Khawaja K. Twenty-year trends in diagnosis of life-threatening neonatal cardiovascular malformations. Arch Dis Child Fetal Neonatal Ed 2008; 93:F33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23385/abstract/35\">",
"      Brown KL, Ridout DA, Hoskote A, et al. Delayed diagnosis of congenital heart disease worsens preoperative condition and outcome of surgery in neonates. Heart 2006; 92:1298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23385/abstract/36\">",
"      Matsui H, Mellander M, Roughton M, et al. Morphological and physiological predictors of fetal aortic coarctation. Circulation 2008; 118:1793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23385/abstract/37\">",
"      Teien DE, Wendel H, Bj&ouml;rnebrink J, Ekelund L. Evaluation of anatomical obstruction by Doppler echocardiography and magnetic resonance imaging in patients with coarctation of the aorta. Br Heart J 1993; 69:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23385/abstract/38\">",
"      Greenberg SB, Balsara RK, Faerber EN. Coarctation of the aorta: diagnostic imaging after corrective surgery. J Thorac Imaging 1995; 10:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23385/abstract/39\">",
"      Lu CW, Wang JK, Chang CI, et al. Noninvasive diagnosis of aortic coarctation in neonates with patent ductus arteriosus. J Pediatr 2006; 148:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23385/abstract/40\">",
"      Nielsen JC, Powell AJ, Gauvreau K, et al. Magnetic resonance imaging predictors of coarctation severity. Circulation 2005; 111:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23385/abstract/41\">",
"      Muzzarelli S, Meadows AK, Ordovas KG, et al. Prediction of hemodynamic severity of coarctation by magnetic resonance imaging. Am J Cardiol 2011; 108:1335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/53/23385/abstract/42\">",
"      Marek J, Skovr&aacute;nek J, Huc&iacute;n B, et al. Seven-year experience of noninvasive preoperative diagnostics in children with congenital heart defects: comprehensive analysis of 2,788 consecutive patients. Cardiology 1995; 86:488.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5760 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-213.134.24.46-B0B7A2AA67-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_53_23385=[""].join("\n");
var outline_f22_53_23385=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS AND ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Congenital",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1053215312\">",
"      - Genetic factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Acquired",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1053215422\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1053215635\">",
"      Anatomical variants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1053215674\">",
"      Other cardiac lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1053215802\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Manifestations according to age",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Neonates",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Older infants and children",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1088179575\">",
"      Natural history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1088179206\">",
"      Physical findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1088178828\">",
"      - Blood pressure and pulses",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Cardiac examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1088179382\">",
"      Tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1088179443\">",
"      - Electrocardiogram",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1088179450\">",
"      - Chest radiograph",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1088180758\">",
"      Noncardiac manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Intracranial hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Turner syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Prenatal diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1088180874\">",
"      Postnatal diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Echocardiography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Magnetic resonance imaging/computed tomography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Cardiac catheterization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1088180658\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5760\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5760|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?31/50/32544\" title=\"diagnostic image 1\">",
"      Infant coarctation of the aorta and heart failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?18/19/18738\" title=\"diagnostic image 2\">",
"      Rib notching coarctation of the aorta",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?25/63/26609\" title=\"diagnostic image 3\">",
"      Chest x-ray coarctation of the aorta 3 sign",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?33/34/34336\" title=\"diagnostic image 4\">",
"      Aortogram coarctation of the aorta 3 sign",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?25/8/25730\" title=\"diagnostic image 5\">",
"      Coarctation aorta Echo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?41/33/42527\" title=\"diagnostic image 6\">",
"      Coarctation aorta PA angiogram",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5760|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/3/41014\" title=\"figure 1\">",
"      Coarcation of the aorta anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/43/15032\" title=\"figure 2\">",
"      Fetal circulation 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/36/44622\" title=\"figure 3\">",
"      Brachial fem artery",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26202?source=related_link\">",
"      Auscultation of cardiac murmurs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/56/22410?source=related_link\">",
"      Auscultation of heart sounds",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/19/13624?source=related_link\">",
"      Clinical features and diagnosis of Takayasu arteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33449?source=related_link\">",
"      Clinical manifestations and diagnosis of Turner syndrome (gonadal dysgenesis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/1/6169?source=related_link\">",
"      Clinical manifestations and diagnosis of bicuspid aortic valve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/52/35656?source=related_link\">",
"      Clinical manifestations and diagnosis of patent ductus arteriosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/45/17113?source=related_link\">",
"      Definition and diagnosis of hypertension in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/13/3285?source=related_link\">",
"      Electrocardiographic diagnosis of left ventricular hypertrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/15/9466?source=related_link\">",
"      Etiology and diagnosis of heart failure in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/2/39975?source=related_link\">",
"      Etiology, clinical manifestations, and evaluation of neonatal shock",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/15/33013?source=related_link\">",
"      Examination of the arterial pulse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/43/9909?source=related_link\">",
"      Examination of the precordial pulsation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24489?source=related_link\">",
"      Inborn errors of metabolism: Epidemiology, pathogenesis, and clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/0/10250?source=related_link\">",
"      Inborn errors of metabolism: Metabolic emergencies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/63/14329?source=related_link\">",
"      Management of Turner syndrome (gonadal dysgenesis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/27/20922?source=related_link\">",
"      Management of coarctation of the aorta",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?40/43/41649?source=related_link\">",
"      Patient information: Aortic coarctation in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/47/25329?source=related_link\">",
"      Patient information: Aortic coarctation in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/21/27991?source=related_link\">",
"      Who should be evaluated for renovascular or other causes of secondary hypertension?",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_53_23386="Ferning of amniotic fluid";
var content_f22_53_23386=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F78666&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F78666&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 570px\">",
"   <div class=\"ttl\">",
"    Ferning of amniotic fluid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 550px; height: 416px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Typical ferning pattern of dried amniotic fluid (400).",
"    <br>",
"     (B, C) Urine and amniotic fluid can be distinguished by microscopic examination of a droplet of the fluid spread and dried on a microscope slide. The proteins in amniotic fluid give the appearance of ferning (B) that is not observed with urine (C).",
"     <br>",
"      (D) Ferning pattern from amniotic fluid.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"       Reproduced with permission from:",
"       <br>",
"        (A) Courtesy of Dr. Dwight Rouse.",
"        <br>",
"         (B) McClatchey KD. Clinical Laboratory Medicine, 2nd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2002.",
"         <br>",
"          (C) McClatchey KD. Clinical Laboratory Medicine, 2nd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2002.",
"          <br>",
"           (D) Beckmann CRB, Ling FW, Smith RP, et al. Obstetrics and Gynecology, 5th Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2006.",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_53_23386=[""].join("\n");
var outline_f22_53_23386=null;
var title_f22_53_23387="ACG guidelines liver disease during pregnancy";
var content_f22_53_23387=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F72172&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F72172&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    American College of Gastroenterology Guidelines: Liver disease in the pregnant patient",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Use of gestational age of the pregnancy is the best guide to the differential diagnosis of liver disease in the pregnant woman",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hyperemesis gravidarum should be considered in the differential diagnosis of abnormal liver tests presenting in the first trimester",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cholestasis of pregnancy is common, and should be considered in the differential diagnosis of abnormal liver tests presenting initially in the second trimester. Affected pregnancies are at increased risk for prematurity and stillbirth, and early delivery should be considered when possible",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HELLP (hemolysis, elevated liver tests, low platelets) syndrome and acute fatty liver of pregnancy should be considered in the differential diagnosis of abnormal liver tests in the second half of pregnancy, usually in the third trimester",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patients with acute fatty liver of pregnancy have true hepatic dysfunction, and may, or may not, have signs of pre-eclampsia and HELLP syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Consider viral or drug-induced hepatitis, gallstone disease, or malignancy in the differential diagnosis of abnormal liver tests in any of the trimesters of pregnancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic hepatitis B or C poses a risk of transmission to the offspring",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Riely CA. Liver disease in the pregnant patient. Am J Gastroenterol 1999; 94:1728.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_53_23387=[""].join("\n");
var outline_f22_53_23387=null;
var title_f22_53_23388="Effects of types of fat";
var content_f22_53_23388=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F56524&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F56524&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Type of fat intake affects cholesterol concentrations",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Diet enriched with",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Saturated fatty acids, g per",
"100g fat",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Trans fatty acids, g per 100g",
"fat",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\" rowspan=\"1\">",
"        Compared with butter-enriched diet",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        LDL-C, percent",
"       </td>",
"       <td class=\"subtitle2\">",
"        HDL-C, percent",
"       </td>",
"       <td class=\"subtitle2\">",
"        TC:HDL-C, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Soybean oil",
"       </td>",
"       <td>",
"        25.0",
"       </td>",
"       <td>",
"        &lt;0.5",
"       </td>",
"       <td>",
"        -12",
"       </td>",
"       <td>",
"        -3",
"       </td>",
"       <td>",
"        -6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Semiliquid margarine",
"       </td>",
"       <td>",
"        27.0",
"       </td>",
"       <td>",
"        &lt;0.5",
"       </td>",
"       <td>",
"        -11",
"       </td>",
"       <td>",
"        -4",
"       </td>",
"       <td>",
"        -5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Soft margarine",
"       </td>",
"       <td>",
"        25.2",
"       </td>",
"       <td>",
"        7.4",
"       </td>",
"       <td>",
"        -9",
"       </td>",
"       <td>",
"        -4",
"       </td>",
"       <td>",
"        -2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Shortening",
"       </td>",
"       <td>",
"        29.3",
"       </td>",
"       <td>",
"        9.9",
"       </td>",
"       <td>",
"        -7",
"       </td>",
"       <td>",
"        -4",
"       </td>",
"       <td>",
"        -1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stick margarine",
"       </td>",
"       <td>",
"        27.0",
"       </td>",
"       <td>",
"        20.1",
"       </td>",
"       <td>",
"        -5",
"       </td>",
"       <td>",
"        -6",
"       </td>",
"       <td>",
"        +4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Butter",
"       </td>",
"       <td>",
"        61.7",
"       </td>",
"       <td>",
"        1.5",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     In an outpatient feeding study, compared with a butter-enriched diet, diets relatively higher in trans fat resulted in smaller reductions in LDL-cholesterol and larger reductions in HDL-cholesterol (HDL-C). The stick margarine diet, highest in trans fatty acids, resulted in a total cholesterol:HDL cholesterol ratio (TC:HDL-C) that was 4 percent higher than the high saturated fat diet. The diets with the most favorable lipid profiles were the soybean and liquid margarine diets, characterized by low amounts of both saturated and trans fatty acids.",
"    </div>",
"    <div class=\"reference\">",
"     Data from Lichtenstein, AH, Ausman, LM, Jalbert, SM, Schaefer, EJ, N Engl J Med 1999; 340:1933.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_53_23388=[""].join("\n");
var outline_f22_53_23388=null;
var title_f22_53_23389="AEDs for other primary generalized seizures";
var content_f22_53_23389=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F68910&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F68910&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Treatment of atypical absence, myoclonic, atonic seizures",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Drugs",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Total daily adult dosage*",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Total daily pediatric dosage*",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Usual dosing interval",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Starting",
"       </td>",
"       <td class=\"subtitle2\">",
"        Maintenance",
"       </td>",
"       <td class=\"subtitle2\">",
"        Starting",
"       </td>",
"       <td class=\"subtitle2\">",
"        Maintenance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"7\">",
"        Atypical absence, myoclonic, atonic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"7\">",
"        Drugs of choice:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Valproate",
"        <sup>",
"         &bull;,&Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        500-1000 mg",
"       </td>",
"       <td>",
"        1000-3500 mg",
"       </td>",
"       <td>",
"        10-15 mg/kg",
"       </td>",
"       <td>",
"        15-60 mg/kg",
"       </td>",
"       <td>",
"        Once/bid/tid",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        <em>",
"         or",
"        </em>",
"        Lamotrigine",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"       <td>",
"        12.5-50 mg",
"        <sup>",
"         &yen;",
"        </sup>",
"       </td>",
"       <td>",
"        100-700 mg",
"        <sup>",
"         &yen;",
"        </sup>",
"       </td>",
"       <td>",
"        0.15-0.6 mg/kg",
"        <sup>",
"         ������",
"        </sup>",
"       </td>",
"       <td>",
"        1-15 mg/kg",
"        <sup>",
"         ������",
"        </sup>",
"       </td>",
"       <td>",
"        Bid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        <em>",
"         or",
"        </em>",
"        Levetiracetam",
"        <sup>",
"         ������",
"        </sup>",
"       </td>",
"       <td>",
"        500-1000 mg",
"       </td>",
"       <td>",
"        1000-3000 mg",
"       </td>",
"       <td>",
"        10-20 mg/kg",
"       </td>",
"       <td>",
"        40-60 mg/kg",
"       </td>",
"       <td>",
"        Bid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"7\">",
"        Alternatives:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Topiramate**",
"       </td>",
"       <td>",
"        25-50 mg",
"       </td>",
"       <td>",
"        200-400 mg",
"       </td>",
"       <td>",
"        1-3 mg/kg",
"       </td>",
"       <td>",
"        5-9 mg/kg",
"       </td>",
"       <td>",
"        Bid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Zonisamide",
"        <sup>",
"         &bull;&bull;",
"        </sup>",
"       </td>",
"       <td>",
"        100 mg",
"       </td>",
"       <td>",
"        100-600 mg",
"       </td>",
"       <td>",
"        1-2 mg/kg",
"        <sup>",
"         &Delta;&Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        6-8 mg/kg",
"        <sup>",
"         &Delta;&Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        Once/bid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Clonazepam",
"       </td>",
"       <td>",
"        1.5 mg",
"       </td>",
"       <td>",
"        1.5-8 mg",
"       </td>",
"       <td>",
"        0.01-0.03 mg/kg",
"       </td>",
"       <td>",
"        0.05-0.2 mg/kg",
"       </td>",
"       <td>",
"        Bid/tid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Felbamate**",
"       </td>",
"       <td>",
"        600-800 mg",
"       </td>",
"       <td>",
"        2400-4800 mg",
"       </td>",
"       <td>",
"        15 mg/kg",
"       </td>",
"       <td>",
"        15-60 mg/kg",
"       </td>",
"       <td>",
"        Bid/qid",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Dosage may need to be adjusted for renal or hepatic impairment, or concomitant use of other drugs.",
"     <br>",
"      &bull; Measurement of serum concentrations may be useful to guide therapy. Usual therapeutic serum concentrations are: carbamazepine 6-12 mcg/mL, phenobarbital 15-35 mcg/mL, phenytoin 10-20 mcg/mL, valproate 50-120 mcg/mL. Some patients achieve complete seizure control at lower concentrations, and occasional patients need higher concentrations.",
"      <br>",
"       &Delta; Not FDA-approved unless absence is involved.",
"       <br>",
"        &loz; Once daily for the extended-release formulation (Depakote ER).",
"        <br>",
"         &sect; FDA-approved for adjunctive therapy in adults and children &ge;2 years old with partial seizures, with Lennox-Gastaut syndrome or with primary generalized seizures, and as monotherapy in adults with partial seizures as a substitute for carbamazepine, phenytoin, phenobarbital or valproate.",
"         <br>",
"          &yen; Starting dosage is 25 mg every other day and maintenance dosage is 100 to 400 mg daily when given with valproate.",
"          <br>",
"           &Dagger; Starting dosage is 0.15 mg/kg daily and maintenance dosage is 1 to 5 mg/kg daily when given with valproate.",
"           <br>",
"            &dagger; FDA-approved as adjunctive therapy for patients 12 years and older with myoclonic seizures.",
"            <br>",
"             ** FDA-approved as adjunctive therapy for patients with Lennox-Gastaut syndrome.",
"             <br>",
"              &bull;&bull; Not FDA-approved for this indication.",
"              <br>",
"               &Delta;&Delta; Not FDA-approved for pediatric use.",
"              </br>",
"             </br>",
"            </br>",
"           </br>",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Drugs for Epilepsy. Treatment guidelines from The Medical Letter 2008; 6(70): 37-46. Copyright &copy;2008 The Medical Letter.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_53_23389=[""].join("\n");
var outline_f22_53_23389=null;
var title_f22_53_23390="Entamoeba histolytica trophozoite";
var content_f22_53_23390=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F57615&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F57615&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Entamoeba histolytica trophozoite: Microscopy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 300px; height: 300px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Trophozoites of E. histolytica with ingested erythrocytes stained with trichrome.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Centers for Disease Control and Prevention. file://www.dpd.cdc.gov/dpdx/html/ImageLibrary/Amebiasis_il.htm.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_53_23390=[""].join("\n");
var outline_f22_53_23390=null;
var title_f22_53_23391="Components of a long bone";
var content_f22_53_23391=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F76662&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F76662&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Components of a long bone",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 333px; height: 499px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This illustration depicts the major components of a long bone.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_53_23391=[""].join("\n");
var outline_f22_53_23391=null;
